DK150690B - Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stofved enzym-immunoanalyse - Google Patents

Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stofved enzym-immunoanalyse Download PDF

Info

Publication number
DK150690B
DK150690B DK639871AA DK639871A DK150690B DK 150690 B DK150690 B DK 150690B DK 639871A A DK639871A A DK 639871AA DK 639871 A DK639871 A DK 639871A DK 150690 B DK150690 B DK 150690B
Authority
DK
Denmark
Prior art keywords
enzyme
antibodies
reaction
specific binding
hcg
Prior art date
Application number
DK639871AA
Other languages
English (en)
Other versions
DK150690C (da
Inventor
Antonius Hermanus Wilh Schuurs
Bauke Klaas Van Weemen
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of DK150690B publication Critical patent/DK150690B/da
Application granted granted Critical
Publication of DK150690C publication Critical patent/DK150690C/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743Steroid hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/539Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
    • G01N33/541Double or second antibody, i.e. precipitating antibody
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/964Chemistry: molecular biology and microbiology including enzyme-ligand conjugate production, e.g. reducing rate of nonproductive linkage
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/971Capture of complex after antigen-antibody reaction
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/807Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808Automated or kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/815Test for named compound or class of compounds
    • Y10S436/817Steroids or hormones
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/815Test for named compound or class of compounds
    • Y10S436/817Steroids or hormones
    • Y10S436/818Human chorionic gonadotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Description

150690 ø
Det er kendt, at en komponent i reaktionen mellem et specifikt binderprotein og det tilsvarende bindelige stof kan bestemmes ved, at man inkuberer en af de omhandlede komponenter forsynet med en markør i en reaktionsblanding, som i det mindste indeholder den anden komponent, 5 og derpå iværksætter en adskillelse mellem den mærkede komponent, som henholdsvis er og ikke er bundet til dens bindingspartner og endelig bestemmer markøren i mindst en af de to fremkomne fraktioner. Fordelingen af den mærkede komponent over de to fraktioner er et mål for den mængde af den søgte komponent, som er til stede i prøven. Der 10 kan beskrives tre systemer, i hvilke den ovennævnte fremgangsmåde kan anvendes, a) antistoffer som specifikke binder-proteiner og de tilsvarende antigener som bindelige stoffer. Stoffer, som kan bestemmes 150690 . 2 på denne måde, er bl, a. proteinhormoner og deres antistoffer eller virus-antigener og deres antistoffer, b) antistoffer som specifikke binder-proteiner og haptener som bindeligt stof. Her defineres hap-tenerne som proteinfri stoffer, der kan reagere med antistoffer uden 5 at være i stand til at inducere dem. Stoffer, som kan bestemmes i et sådant system, er bl.a. steroidhormoner og vitaminer, c) proteiner, som i legemet virker som receptor- eller transport-molekyler som specifikke binder-proteiner og stoffer, som er bundet af dem som binde-lige stoffer. Dette system er f.eks. egnet til bestemmelse af ste-10 roidhormoner, men også af thyroxin og triiodthyronin, vitamin B12, den intrinsicole faktor og det adrenocorticotrope hormon.
De vigtigste punkter i de beskrevne analysemetoder er anvendelsen af en markør og adskillelsen af den mærkede komponent i en fraktion, 15 som er bundet, og en fraktion, som ikke er bundet til den tilsvarende komponent.
Fra beskrivelsen til dansk patentansøgning nr. 5462/71 kendes en fremgangsmåde, ved hvilken der anvendes enzymmærket komponent i forbindel-20 se med en kvantitativ immunologisk bestemmelse. Ved denne kendte fremgangsmåde sker adskillelsen mellem flydende og fast fase ved gelfiltrering, men denne metode er upraktisk og kan ikke give nogen pålidelig og let bestemmelse. Ved metoden kan immunokomponenter kun bestemmes i en koncentration på 50-100 nanogram pr. milliliter.
25
Fra beskrivelsen til dansk patentansøgning nr. 2812/67 kendes endvidere en fremgangsmåde, ved hvilken der gøres brug af uopløseliggjorte antistoffer overfor proteiner eller peptider, som er antigener, i en radio-immun bestemmelse. Radiaktive atomer anvendt som markører er 30 f.eks. 131j, 125^, 14^, 3^, 5?Co Denne fremgangsmåde er kendetegnet ved en høj følsomhed. Imidlertid er denne fremgangsmåde begrænset til institutter, hvor det nødvendige specielle apparatur er tilgængeligt.
Adskillelsesmetoderne kan opdeles på følgende måde: 35 a) Fremgangsmåder afhængige af forskellen i fysiske egenskaber mellem den ikke bundne, mærkede komponent og dens kompleks med bindings-partneren, såsom gel-filtrering, elektroforese, saltudfældning og absorption til dekstran-overtrukket trækul.
40 b. Den såkaldte fastfase-metode, ved hvilken den ene komponent allerede i forvejen er bragt i uopløselig form ved tværbinding eller ved 3 150690 covalent binding eller fysisk adsorption til en fast bærer, c) Den såkaldte dobbelte antistof«metode,ifølge hvilken det dannede kompleks, antigen (eller hapten)«antistof udfældes ved hjælp af antistoffer over for antistoffet i komplekset, hvilken fremgangsmåde 5 kun er kendt fra systemer, i hvilke antistoffer i opløst form kommer i betragtning«
Medens de under a) og c) omtalte fremgangsmåder er relativt komplicerede, lider de under b) omtalte af den ulempe, at en reaktions-10 komponent, når den bringes i uopløselig form, som regel vil mindske sin affinitet til reaktions-partneren. Imidlertid er en høj affinit« vigtig for tilvejebringelse af et følsomt prøvesystem.
Ifølge opfindelsen har man fundet en fremgangsmåde til bestemmelse 15 af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stof under anvendelse af den kendte bindingsaffinitet af sådanne komponenter indbyrdes, idet man ved bestemmelsen anvender en kendt mængde af et koblingsprodukt af det bindelige stof med et enzym og eventuelt også en kendt mængde af det 20 specifikke binderprotein (i det tilfælde, at det bindelige stof er den komponent, der skal bestemmes), hvilken fremgangsmåde er ejendommelig ved, at man yderligere anvender . uopløseliggjo.rte antistoffer oVér for det-< specif ikke binder-protein,·' og at man efter reaktionen bestemmer enzymaktiviteten i den flydende eller 25 faste fase af reaktionsblandingen. Denne fremgangsmåde muliggør bestemmelse af komponenter, der er til stede i en koncentration på 1-1C nanogram pr. milliliter.
I den foreliggende beskrivelse bruges begreberne conjugat og enzym-30 conjugat synonymt for koblingsproduktet af det bindelige stof og enzymet.
Det bindelige stof kan opdages og bestemmes ved, at man sammenbringer den ukendte prøve eller en fortyndingsserie af samme med en kendt 35 mængde af et conjugat af det stof, der skal bestemmes, og et enzym og med en mængde specifikt binderprotein i afhængighed af den mængde enzym-conjugat, som tilsættes. Derpå tilsættes en mængde, fortrinsvis et overskud af de antistoffer, der er gjort uopløselige over for det specifikke binder-protein, så at hele enzym-conjugatet, som har 40 reageret med binder-proteinet, ved hjælp af dette protein bliver koblet til disse uopløselige antistoffer. Jo mere bindeligt stof der ex 4 150690 til stede i prøven, jo mindre enzym-conjugat vil reagere med det specifikke binder-protein og sluttelig komme i den uopløselige fase. Resultatet bliver, at mere ubundet enzym-conjugat forbliver i den flydende fase og på simpel måde kan bestemmes der. Det specifikke 5 binder-protein kan bestemmes ved, at man inkuberer prøven eller fortyndingsserier af denne med en kendt mængde enzym-conjugat og med en mængde af de over for det specifikke binder-protein uopløselig-gjorte antistoffer. Enzymaktiviteten kan kun finde sted i den uopløselige fase, hvis conjugatet har reageret med det specifikke bin-10 der-protein, d.v.s. jo mere specifikt binder-protein, der er i prøven, jo mindre bundet enzym-conjugat vil forblive i den flydende fase.
Den beskrevne analyse-metodes følsomhed kan varieres ved at ændre mængderne af reagenserne. Imidlertid er den mængde enzym-conjugat, 15 som kan anvendes, begrænset nedefter af kravet om, at dets enzymaktivitet kan måles på rimelig måde, hvorfor analyse-metodens følsomhed har sin begrænsning. Den minimalt målelige enzym-aktivitet er bl. a. afhængig af naturen af det enzym, der anvendes ved koblingen, og af substratets natur og endelig af enzym-reaktionens 20 inkubationstid. Fremdeles indvirker det specifikke binder-proteins affinitet stærkt på bestemmelsens følsomhed. Ved en analyse-metode af høj følsomhed kræves specifikke binder-proteiner med en høj affinitet.
25 Mængderne af de for en bestemmelse nødvendige reagenser må fastlægges ad empirisk vej.
Til bestemmelsen af det bindelige stof må mængden af enzym-conjugatet bestemmes ved hjælp af enzymaktiviteten. Derpå inkuberes denne mængde 30 med en fortyndingsserie af det specifikke binder-protein til bestemmelse af den nødvendige mængde af dette protein. Fortrinsvis vælger man en mængde specifikt binderprotein, som kan binde 50-90% af enzym-conjugatet. Til sidst undersøger man, hvorvidt den ønskede følsomhed så er blevet nået, idet man undersøger en fortyndingsserie af 35 det stof, der skal undersøges ved metoden.
Til bestemmelsen af det specifikke binder-protein må der angående doseringen af enzym-conjugatet tages hensyn til dettes aktivitet, som skal kunne bestemmes med rimelig nøjagtighed.
s 150690
De antistoffer over for det specifikke binder-protein, der er gjort uopløselige, tilsættes fortrinsvis i overskud ved de to bestemmelses-måder. Disses dosering bestemmes ved forudgående forsøg.
5 Denne fremgangsmådes fordele over for de kendte er, at kombinationen af "Dobbelt Antistof" og "Fast Fase"-metoden, i det følgende af bekvemmelighedsgrunde betegnet DASP-metoden, frembyder adskillige fordele over for de kendte fremgangsmåder. Således er udførelsen af den nye fremgangsmåde, d.v.s. tilførsel af uopløseliggjorte anti-10 stoffer over for det specifikke binder-protein, inkubation, centrifugering og måling, meget simpel, doseringen er ofte lettere end ved fast-fase-metoderne, fordi det er tilstrækkeligt at tilsætte et overskud af uopløst materiale, hvorimod man ved fast-fase-metoderne skal bruge en nøjagtigt udmålt mængde af det faste materiale. Frem-15 deles er affiniteten hos binder-proteinet til det bindelige stof ikke svækket af bindingen til bærermaterialet, således som det kan være tilfældet ved fast-fase-metoden. En yderligere fordel over for den sidste fremgangsmåde er den hurtige ligevægt-indstilling hos reaktionen mellem det specifikke binder-protein og det bindelige stof 20 (begge i opløsning). En yderligere fordel består i, at ved DASP- fremgangsmåden kan det uopløseliggjorte antistof, nedenfor betegnet immunoadsorbenten, bruges i ethvert system, i hvilket man bruger antistoffer som specifikke binder-proteiner, forudsat at disse antistoffer er præpareret i de samme dyrearter. På den anden side, for 25 ethvert antigen eller hapten, der skal bestemmes efter fast-fase-metoden, skal antistofferne gøres uopløselige. Den dobbelte antistofmetode er meget følsom over for relativt små ændringer i saltkoncentrationerne, pH og lignende, som gør en vidtgående kontrol af betingelserne nødvendig. Yderligere kræver metoden tilføjelse af 30 "bærer"-γ-globulin og følgelig meget andet antistof til opnåelse af et immunt precipitat. Foruden at være en mere enkel fremgangsmåde fører DASP-metoden, som ikke kræver "bærer"-γ-globulin, til besparelse af materialer. Endelig skal det nævnes, at en dobbelt antistoflignende adskillelse anvendt ved transport- eller receptor-proteiner 35 ikke er mulig, da der ikke kan fremskaffes et "bærer"-protein til dette formål. Fremgangsmåden ifølge opfindelsen frembyder derfor en enestående lejlighed i denne henseende.
Fremgangsmåden ifølge opfindelsen kan let gøres automatisk. Det er 40 principielt muligt at bringe reaktionskomponenterne sammen straks _ t t _ . i _ j . _ -? , » t_ _ i i ^ ^___ ^ r Λ__i · T __ __ i i____ 6 150690 man dog fortrinsvis de uopløselige antistoffer over for det specifikke binder-protein til reaktionsblandingen som det sidste reagens, idet det har vist sig, at bestemmelsen derved får en højere følsomhed.
5
Ved fremgangsmådens anvendelse til bestemmelse af det bindelige stof går man af samme grund hensigtsmæssigt frem på den måde, at man først til prøven sætter det specifikke binder-protein og derpå enzym-con-jugatet og til sidst de uopløselige antistoffer over for det speci-fikke binder-protein.
Det for opfindelsen nødvendige reagens, d.v.s. koblingsproduktet af antigen, hapten eller det bindelige stof med enzymet, kan fremstilles på kendt måde. Disse fremgangsmåder kan også bruges til at bin-15 de et hapten eller et lavmolekulært bindeligt stof til et enzym, forudsat at et af stofferne har en eller flere aminogrupper og det andet en eller flere carboxylgrupper. Hvis det sidste ikke er tilfældet, er det muligt at indføre den ønskede gruppe i molekylet, som skal kobles, ved hjælp af en kendt organokemisk proces. Der kendes 20 også fremgangsmåder til sammenbinding af amino- og carboxylgrupper, eventuelt ved at indføre en bro. Endelig kan komponenter som glutar-aldehyd, difluordinitrodiphenylsulfon og di- og tri-chloro-s-tria= zin ofte anvendes til den omhandlede kobling. Det kan blive nødvendigt at adskille de fremstillede enzymconjugater fra uomdannede stof-25 fer og fra stoffer, som er blevet inaktive. Til dette formål kan man benytte kendte fremgangsmåder, såsom udfældning med organiske opløsningsmidler, gelfiltration og centrifugering ved en vægtfyldegradient .
20 Valget af det enzym, der benyttes i koblingsproduktet, er bestemt ved et antal egenskaber hos enzymet. Naturligvis er det vigtigt, at enzymet er resistent over for koblingen med et andet molekyle, d.v.s. over for ændring af en eller flere aminosyre-sidekæder. Enzymets specifikke aktivitet er også af stor vigtighed. Da en mindre mæng-25 de enzym—conjugat behøver at tilføjes for at opnå en målelig enzympåvirkning, bliver undersøgelsessystemet mere følsomt. Fremdeles bør man foretrække de enzymer, hos hvilke en bestemmelse af aktiviteten kan foretages på en simpel måde, I første række bør man tage de enzymer i betragtning, for hvilke aktiviteten kan béstemmes kolorime-40. trisk, épektrofotometrisk eller fluorimetrisk. Sådanne bestemmelser 7 150690
Man kan bestemme aktiviteten af de, .enzymer kolorimetrisk, som katalyserer en reaktion, ved hvilken der. .opstår eller forsvinder et farvet stof, enten ved den primære eller den sekundære reaktion.
5 Som enzymer, der- kan" anvendes som den enzymatisk; aktive komponent i conjugater, skal nævnes catalase, peroxidase (3-glucoronidase, β-D-glucosidase, β-D-galactosidase, urease, glucose-oxidase, galactose-oxidase og alkalisk phosphatase.
10 Ved afslutningen af reaktionen mellem komponenterne og reagenserne kc man ifølge opfindelsen bestemme enzymaktiviteten i den flydende ellei den faste fase, eller i begge faserne af reaktionsblandingen. Det simpleste er imidlertid at bestemme enzymaktiviteten i den flydende fase, 15
De antistoffer, der er gjort uopløselige over for de specifikke binde proteiner, som også er vigtige reagenser for fremgangsmåden ifølge op findelsen, kan også fremstilles på kendt måde. Antistofferne kan fremstilles, idet man tager et renset præparat af det specifikke bin-20 der-protein eller af de proteiner, som har i det mindste delvis de sa me antigen-egenskaber som det specifikke binder-protein, og så injice rer dette på kendt måde i en anden dyreart end den, fra hvilken man fik det. Det behandlede dyrs serum eller gamma-globulin-fraktionen af dette kan gøres uopløseligt ved kryds-led-forbindelse med sådanne sto 25 fer som glutaraldehyd og chlormyresyre-ethylester eller ved binding t faste bærerpartikler enten fysisk eller adsorptivt eller kemisk ved dannelse af covalente bindinger. Som faste bærere kan anvendes sådanm stoffer som cellulose (ændret eller ikke), agarose, kryds-led-forbundi dekstran, polystyren og lignende. En covalent binding til disse stof· 30 fer af antistoffer kan foretages ved hjælp af sådanne stoffer som car: bodiimider, di- og tri-chloro-s-triaziner, glutaraldehyd, cyanogenbro-mid og f.eks. ved diazotering.
Fordelene ved fremgangsmåden ifølge opfindelsen til bestemmelse af 35 binderprotein opnås, hvis man anvender et overskud af uopløselige ant: stoffer, således at det specifikke binderprotein går helt over i den faste fase.
De former, i hvilke reagenserne kan anvendes, er mangfoldige. Den 40 enzym-conjugerede komponent i reaktionssysternet kan frysetørres eller 8 150690 opløses i en stødpude. Man kan også bruge en fast bærer, f,eks. en papirstrimmel imprægneret med conjugatet. Denne anvendes også til de nødvendige binder-proteiner.
Den uopløselige komponent kan bringes i form af partikler af forskellig størrelse, såsom granuler, flager, stave eller i form af en strimmel af et eller andet bæremateriale.
Opfindelsen angår endvidere en analysepakke til bestemmelse af * et specifikt binder-protein eller det tilsvarende bindelige stof ved den beskrevne fremgangsmåde, hvilken analysepakke er ejendommelig ved at den hovedsagelig indeholder: a) en kendt mængde conjugat af det bindelige stof og et enzym, ’ b) en kendt mængde binder-protein, hvis analysepakken skal anvendes til bestemmelse af det bindelige stof, c) én kendt mængde uopløseliggjorte antistoffer rettede imod det binderprotein, som er tilsat, eller som skal bestemmes, d) et substrat til bestemmelse af aktiviteten af det anvendte enzym.
i
Analysepakken kan fremdeles indeholde de nødvendige yderligere midler til analysens udførelse, såsom reagensglas, pipetter og flasker med opløsninger.
Analysepakken kan særlig hyppigt og med særlig fordel anvendes til opdagelse og bestemmelse af et antigen eller et hapten, og til dette formål indeholder den i hovedsagen: a) en kendt mængde af et conjugat af antigenet eller haptenet og et enzym, b) en tilsvarende mængde af tilsvarende antistoffer, c) en kendt mængde uopløseliggjorte antistoffer, rettede imod de anvendte antistoffer, d) et substrat til bestemmelse af aktiviteten af det anvendte enzym.
Når man anvender sådanne analysepakker til påvisning og bestemmelse af antistoffer, behøver man ikke de under b) nævnte antistoffer.
150690 9
En vigtig udførelsesform for en analysepakke ifølge opfindelsen er én ana-lysepakke til bestemmelse af de gonadotrope hormoner og særlig til bestem' melse af HCG (Human Chorionic Gonadotropin) som et middel til bestemmelse 5 af graviditet allerede på et meget tidligt stadium, hvilken analysepakke er ejendommelig ved, at den består af en beholder, der som væsentlige bestanddele i lyofiliserede lag indeholder: a) en bestemt mængde af et HCG-conjugat og et enzym, f.eks. HCG-peroxidase b) en bestemt mængde anti-HCG, c) en bestemt mængde uopløseliggjorte antistoffer oyer for anti-HCG sammei med et substrat til bestemmelse af enzymaktiviteten af det resterende HCG-enzym i den flydende fase.
Ved tilsætning af en vis mængde urin fra en formodet gravid kvinde, til 15 denne analyseblanding og ved at inkubere urinen med disse bestanddele dannes der en blanding af uopløseligt stof, idet den øvrige del indeholder det tilbageblevne opløselige HCG-enzym-conjugat. Mængden af det sidste afhænger af mængden af HCG i den undersøgte urin. Ved bestemmelse af enzymaktiviteten hos dette tilbageblevne HCG-enzym-conjugat kan man 20 fastslå, om urinen skyldes en gravid kvinde eller ej.
En fremgangsmåde, der fortrinsvis anvendes ved bestemmelsen af enzymaktiviteten, består i, at man bringer et indikator-papir imprægneret med enzymreagenser, f.eks, hvis der bruges en peroxidase, en H„09-forsyner så- 25 ^ ^ som urinstof-EL^,med et farvereagens såsom o-tolidin.
Ved korrekt valg af mængderne af hvert af reagenserne bliver det muligt at fastslå graviditet allerede på et meget tidligt stadium og på en simpel, hurtig og meget pålidelig måde, som kan udføres af en ikke opøvet 30 person.
150690 10
Eksempel 1.
Bestemmelse af det menneskelige chloriongonadotropin (HCG).
5 a) Fremstilling af HCG-HRP.
5 mg HCG og 20 mg peberrods-peroxidase (HRP) opløses i 2 ml 0,05 M phosphat-stødpude med pH-værdien 6,2. Efter tilsætning af ko μΐ 25$ glutaraldehyd-ορløsning rystedes “blandingen i 2 timer ved stuetemperatur. Efter 5 minutters centrifugering ved 250 g fraktioneredes væsken over Sephadex G-200 i 0,05 M phosphat= stødpude med pH-værdien 6,2. Fraktionerne, hos hvilke den højeste enzymaktivitets $ var bundet af antistoffer overfor HCG brugtes under analysen.
15 b) Fremstilling af antistoffer overfor HCG.
Antistoffer overfor HCG indiceredes i kaniner som angivet af Schuurs et al. Acta Endocr. (Kbh) 59j 120,(1968).
c) Fremstilling af antistoffer overfor kanin-y-globulin.
2q Kanin-Y-globulin isoleredes fra normalt kanin-serum ved udfældning med l8$ w/v fast natriumsulfat. Antistoffer overfor dette fremstilledes ved immunisering af et får i overensstemmelse med følgende skemai 25 dag mængde Freud's adjuvans injektionsmåde 0 o,5 mg + intramuscular 1^· o,5 mg + intramuscular 28 1 mg + intramuscular b2 1 mg - intravenøs 3Q 56 1 mg - intravenøs den 70.dag blev fåret åreladt.
d) Fremstilling af immunoadsorbent-eellulose /får-anti-(kanin-γ-globu= 35 lin)7.
γ-globulinfraktionen af fåre-serumet beskrevet under c) fremstilledes ved udfældning med 165¾ w/v fast natriumsulfat. Efter vaskning optoges udfældningen i så meget 0,05 M borat-stødpude med pH-værdien 8,6, at den fremkomne proteinkoncentration udgjorte 10 mg/ml.
4Q 350 mg m-aminobenzyloxymethylcellulose opslemmedes i 50 ml destilleret 11 15069¾ vand og diazoteredes ved tilsætning af 10 ml 30$ saltsyre og dråbevis tilsætning af 10 ml 10$ NaDiK^-opløsning ved 0°C. Op-slemningen centrifugeres. Den vaskedes, og bundfaldet resuspendere-des i *+3 ml 0,05 M natriumborat med pH-værdien 8,6, derpå tilsattes 5 7 ml af den fremstillede γ-globin-opløsning. Blandingen omrørtes i 26 timer ved å-°C, hvorpå den centrifugeredes og vaskedes med 0,02 M phosphat-stødpude med pH-værdien 6,0.
e) Bestemmelse af HCG
10 Der fremstilledes en fortyndingsserie (32 -16-8-^-2-1-o,5-IU/ml) af HCG i 0,02 M phosphat-stødpude med pH-værdien 6,0, som indeholdt 2$ v/v normalt fåreserum.
0,5 ml af hver af de HCG-indeholdende prøver inkuberedes med 0,1 ml kanin-(anti-HCG)-serum og 0,1 ml HCG-KRP-conjugat, begge i passen-15 de fortynding i eii halv time’ved stuetemperatur. Derpå tilsatte 0,3 ml af immunoadsorbenten (10 mg/ml) fremstillet ifølge d),og den fremkomne blanding omrørtes i en time ved stuetemperatur. Efter centrifugering bestemtes enzymaktiviteten: resten ved at blande 0,5 ml .
af denne væske med 1,5 ml substrat (10μ1 30$ ^.$2 °& 20 mg 5-amino--20 salicylsyre i 150 ml 0,02 M phosphatstødpude med pH-værdien.6,0), og efter 30 minutter ved 25°C måltes ekstinctionen ved 1+60 mm.
På denne måde påvistes det, at det var muligt at opdage en HCG-koncentration fra 0,5 til lIU/ml i prøven. Ved denne metode kunne man også undersøge urinprøver. Undersøgelsen er derfor egnet til 25 en graviditetsprøve. Forholdet til en eksisterende undersøgelsesmetode, en hæmaglutinations-·inhibitions-prøve var god. Det påvistes muligt at forøge systemets følsomhed ved anvendelse af en pre-incubation. Her incubereres prøven først med antiserumet og derpå tilsattes HCG-HRP-conjugatet.
30
Eksempel II.
Bestemmelse af insulin og anti-insulin.
a) fremstilling af insulin-(glucose-oxidase).
35 Der opløstes 5 mg grise-insulin af 25 mg glucose-oxidase i 2 ml 0,05 M phosphat-stødpude med pH-værdien 6,5. Hertil sættes 5 μΐ glutaraldehyd-opløsning, hvorefter blandingen rystedes i 90 minutter ved stuetemperatur. Blandingen fraktionereres over Sephadex 150690 12 G-200 i 0,05 M phosphat-stødpude med pH-værdien 6,5.De .fraktioner, af hvilke den højeste procentiske enzym-aktivitet kunne hindes af antistoffer overfor insulin, anvendtes ved analysen 5 b) Fremstilling af antistoffer overfor insulin.
Man ggv·' 10 marsvin &n;- ugentlig intramuskulær injektion med 1 mg grise-insulin i fuldstændig Freud's adjuvans gennem en periode på ^+-8 uger. Efter 10 ugers hvile gav man dyrene yderligere 1 mg insulin ved intravenøs injektion uden adjuvans. To uger senere blev 10 dyrene åreladt. Man modarbejdede den tilstødende hypoglycæmi ved intraperional administration af glucose.
c) Fremstilling af antistoffer ' overfor. maxsvin-γ-globulin.
Der . fremstilledes marsvin-Y-globulin ved tilsætning af 1 15 volumen ^mættet ammoniumsulfat-opløsninq til 2 volumen marsvine- serum. Den fremkomne udskillelse vaskedes to gange med 33i° mættet ammoniumsulfat-opløsning, hvorefter den optoges i en fysiologisk saltopløsning. Derpå immuniseredes et får med voksende doser af det fremstillede γ-globulin: 0,5 - 1 og 2 mg. Injektionerne blev 20 givet hver anden uge, idet immunogenet var blandet med fuldstændig
Freud's adjuvans. To uger efter den sidste injektion gaves der yderligere 2 mg γ-globulin i en fysiologisk saltopløsning, og en uge senere blev dyret åreladt.
25 d) Fremstilling af uopløselige antistoffer overfor marsvin-Y-globulin.
10 g mikrokrystallinsk cellulose aktiveredes ved, at det under omrøring sattes til H00 ml 2,5$ w/v CWBr-opløsning, hvorefter pH-værdien øgedes til 10,5 nied 1 N NaOH-opløsning, idet denne værdi opret 30 holdtes i 2 minutter. Derpå vaskedes cellulosen med isvand og med 0,1 M NaHCOy Der tilsattes 1,6 g Na^SO^ til 10 ml fåre-anti( marsvin.-γ-globulin) -serum. Efter en times omrøring ved stuetemperatur centrifugeres udfældningen. Der vaskedes to gange med 20 ml 16$ w/v Na^O^-opløsning, hvorefter det optoges i 10 ml 0,1 M NaHCO^-35 opløsning. Den aktiverede cellulose blandedes med *+0 ml 0,1 M NåKCO^- opløsning og de 10 ml γ-globulin-opløsning. Denne suspension om-rørtes i ^0 timer ved ^°0 og vaskedes efterhånden to gange med 150690 13 500 ml 0,5 M NaHCO^j to gange med 500 ml 0,05 M citrat af pH-værdien 1,1 og to gange med 500 ml 0,05 M phosphat af pH-værdien 6?5 5 e) Bestemmelse af antistoffer overfor insulin.
0,1 ml insulin-(glucose-oxidase) inkuberedes i passende fortynding med 0,*+ ml af en fortynding s serie af en marsvin-anti-insulin-serum i timer. Fortynding s s er i en foretoges med 0,05 M phosphat-stødpude med pH-værdien 6,0. Derpå tilsattes 0,3 ml immunoadsorbent 10 (15 mg/ml) og 0,2 ml stødpude, og blandingen omrørtes natten over ved *f°C. Efter centrifugering bestemtes enzymaktiviteten'af den resterende opløsning ved incubering af 0,5 ml af denne med 2,5 ml substrat i 30 minutter, hvorpå man målte ekstinetionen ved *+60 nm. Substratet indeholdt 50 mg glucose, 10 μg peroxidase og 1 mg 15 5- amino salicyl syre pr. 2,5 ml 0,05 M phosphat-stødpude med pH-værdien 6,0.
Med dette system kunne antistofindholdet i de forskellige slags serum sammenlignes. Som referencepunkt valgtes den serumfortynding, hvor 5o5 af den totale kombinerbare enzymaktivitet er bundet.
20 f) Bestemmelse af insulin.
0,2 ml af en fortyndingsserie af insulin incuberedes i 2 timer med 0,1+ ml anti-insulin-serum i en sådan fortynding, at den kunne binde 60$ af det tilsatte enzym-conjugat. Derpå tilsattes 0,1 ml 25 insulin-(glucose-oxidase) · des i timer. Endelig tilsattes 0,3 ml immunoadsorbent (15 mg/ml). Blandingen omrørtes natten over ved H°C. Efter centrifugering måltes enzymaktiviteten i resto. løsningen som angivet under e). Bestemmelsens følsomhed, som afhænger af det anvendte antiserum, lig-30 ger indenfor nanogram-ordenen: 20-100 mg/ml, d.v.s* 0,5-2,5 mU/ml.
Eksempel III.
Bestemmelse af oestradiol.
35 a) Fremstilling af oestradiol-17-succinyl-HRP.
50 mg oestradiol-17-hemisuceinat og 0,08 ml tri-n-butylamin opløstes i 2,5 ml dioxan. Til den kolde (2°C) opløsning sattes 15 Hl isobutylchlorocarbonat. Efter 3o minutter blandedes denne opløsning
lif T5069Q
med 100 mg peberrodsperoxidase (HRP) i 7?5 ml af en dioxan/vand-blanding (2:3)5 som var indstillet til en pH-værdi på 9j5 med natriumhydroxid. Opløsningen omrørtes i *+ timer ved 2°C og dialyseredes derpå i 18 timer. Udfældningen, der var dannet efter at dialysatets 5 pH-værdi var indstillet til *+,6, centrifugeredes fra, vaskedes og op toges i 5 ml destilleret vand, som var indstillet til en pH-værdi på 8. Stoffet rensedes yderligere ved to ganges udfældning med 10 ml acetone. Det færdige produkt optoges i 10 ml 0,05 M piiospliat-stødpude med pH-værdien 738.
10 b) Fremstilling af østradiol-17-suecinyl-BSA.
Fremstillingen foretoges ifølge den blandede anhydrid-metode, som er angivet i eksempel Illa. Denne fremstilling foretoges, idet man gik ud fra 100 mg østradiol-17-hemisuccinat og 150 mg hornkvægsse-15 rum-albumin (BSA).
c) Fremstilling af antistoffer overfor østradiol.
Man injicerede et får en gang i *+ uger med k mg østradiol-17-succinyl-BSA i fuldstændig Freund's adjuvans. Med regelmæssige mellem 20 rum udtoges der blod fra dyret. Serumet absorberedes med BSA, som var gjort uopløseligt.
d) Fremstilling af antistoffer overfor fåre-Y-globulin.
Der fremstilledes fåre-Y-globulin som angivet i eksempel I, men nu 25 med 16$ w/v natriumsulfat. Man immunicerede så kaniner med denne fåre-Y-globulin efter følgende skema:
Dag mængde Freund's ad.iuvans innektionsmåde 0 200 ^g + intramuskulær 30 lb *+00 μg + ' " 28 800 μg + " b2 800 ug - intravenøs o c 2 Uger efter den sidste injektion blev dyret åreladt.
i5 150690 e) Fremstilling af immunoadsorbenten /kanin-anti (-fåre-Y-globulin)_7-cellulose.
Y-Globulinfraktionen fra de antisera, der er angivet under d), fremstilledes ved udfældning med 18$ w/v Wa^SO^. Det fremkomne produkt 5 kobledes med cellulose efter Gurvich's metode, angivet i eksempel I.
f) Bestemmelse af østradiol.
Immunreaktionen udførtes i 0,02 M phosphat-stødpude med pH-værdien 6,0, som indeholdt 2$ BSA.
10 5 ml af prøven blandedes med 0,1 ml af fåre-anti-østradiolserumet i den ønskede fortynding. Efter 30 minutters inkubation ved stuetemperatur tilsattes 0,1 ml østradiol-17-succinyl-HRP i en passende fortynding, hvorefter der fulgte en anden 30 minutters inkubation 15 ved stuetemperatur. Derpå tilsattes Qf3 ml immunoadsorbent"su" spension (30 mg/mll, og blandingen omrørtes i 2 timer ved stue" temperatur. Derpå adskiltes den flydende og den faste fase ved centrifugering. Enzymaktiviteten i den flydende bestanddel måltes som angivet i eksempel I. Man kunne anvende fåre-anti-østradiol-20 serumet i fortyndinger fra 1:1600 til 1:12800 i afhængighed af kva liteten af det anvendte østradiol-17-succinyl-HRP. Ved en fortynding af 1:12800 af antiserumet kunne en østradiol-koncentration på 10 ng/ml opdages i prøven. Østradiol og østron viste en krydsreaktion i dette system.
25
Eksempel IV
Bestemmelse af cortisol og corticoid-bindende globulin.
a) Fremstilling af cortisol-21-(galaktose-oxidase).
30 Man koblede 50 mg cortisol-21-hemisuccinat og 100 mg galaktose- oxidase ved hjælp af den blandede anhydrid-teknik angivet i eksempel Illa.
b) Corticoid-bindende globulin (CBG) isoleredes fra human serum ved 35 hjælp af successions-kromatografi over DEAE-cellulose og hydroxyl- apatit.
Antistoffer overfor dette fremstilledes ved injicering af kaniner i 1^—dagesmellemrum med 500 Pg CBG i fuldstændig Freund's adjuvans.
Efter 3 måneder injiceredes dyrene med 1 mg CBG, og 2 uger senere i6 150690 c) γ-Globulin- fraktionen af anti-CBG- serum koblede s til m- aminobenzy1= oxymethylcellulose som angivet i eksempel III.
d) Bestemmelse af cortisol.
5 0,5 nil af en prøve, der indeholdt cortisol (standard-opløsning) ekstraheredes med 2 x 3 nil methylenchlorid. Den sammenbragte ekstraktionsvæske inddampedes til tørhed. Residuenten optoges i 0,5 ml 0,05 M phosphat-stødpude med pH-værdien 6,2. Derpå blandedes med 0,1 ml af en opløsning af CBG i den samme stødpude i en passende 10 koncentration, og der inkuberedes i 30 minutter ved h°C. Derpå tilsattes 0,1 ml cortisol-21-(galaktose-oxidase), også i passende fortyndingjOg 0,3 ml af immunoadsorbenten, der fremstilledes under c), med en koncentration af 5 mg/ml. Den fremkomne blanding omrør-tes i 2 timer ved ^°0 og derpå centrifugeredes, hvorefter enzymakti-15 viteten måltes i restvæsken. I den anledning tilsattes 0,5 nil af samme til 1,5 ml substrat bestående af 100 mg D-galaktose, 20 mg 5-aminosalicylsyre og 10 Mg peroxidase i 150 ml 0,02 M phosphat-stødpude med pH-værdien 6,0. Efter 30 minutter måltes ekstinctionen ved *+60 nm. Ved anvendelse af en CBG-koncentration på O,1* Mg/ml og 20 'så meget cortisol-21-(galaktose-oxidase), at 80$ af enzym-konjugatet var bundet til immunoadsorbenten, uden at der tilføjedes steroider, viste det sig muligt at bestemme mængder af fra 3 til 30 ng cortisol e) Bestemmelse af CBG var også mulig med de angivne reagenser. Fra en 25 fortyndingsserie af transcortin, rækkende fra O til 1280 ng/ml in kuberedes 0,5 ml i 15 minutter med 0,2 ml cortisol-21-(galaktose-oxidase) i passende fortynding. Derpå tilsattes 0,3 ml immunoad-sorbent-suspension (5 mg/ml), og blandingen omrørtes i 15 minutter. De to inkubationer holdtes ved Η-°ϋ. Derpå måltes enzymaktiviteten 30 i restvæsken som under d) c Analysemetodens følsomhed viste sig at være 50 ng/ml).
Eksempel V
35 I en flaske lyofiliseredes efterhånden følgende reagenser i adskilte lag: 0,3 ml af immunoadsorbent-suspensionen (10 mg/ml) som angivet i eksempel la.
40 2) 0,1 ml af en Ifo mannitol-opløsning.

Claims (2)

17 150.690 3) 0,1 nil af HCG-HRP som angivet i eksempel la. et andet lag af 0,1 ml af en 1} mannitol-opløsning. 5) 0,1 ml af kanin(anti-HCG)-serum som angivet i eksempel II. 5 Til denne lyofiliserede Handing sattes 0,5 ml af en urinprøve og derpå 0,5 ml destilleret vand. Efter 10 minutter bestemtes enzymaktiviteten i restvæsken ved hjælp af en papirstrimmel imprægneret med urinstof-hydrogenperoxid og o-tolidin. 10 Såfremt urinprøven stammede fra en gravid kvinde (> 2 IU HCG/ml), fremkom der en blå farve indenfor 5 minutter, hvorimod der, når urinprøven stammede fra en ikke-gravid kvinde, ikke fremkom nogen farve indenfor den samme tid. 15 „ ^ Patentkrav *
1. Fremgangsmåde til bestemmelse af en komponent i reaktionen 2Q mellem et specifikt binder-protein og det tilsvarende bindelige stof under anvendelse af den kendte bindingsaffinitet af sådanne komponenter indbyrdes, idet man ved bestemmelsen anvender en kendt mængde af et kob'lingsprodukt af det bindelige stof med et enzym og eventuelt også en kendt mængde af det specifikke binderyprotein 25 (i det tilfælde, at det bindelige stof er den komponent, der skal bestemmes), kendetegnet ved, at man yderligere anvender uopløseliggiorte antistoffer over for det specifikke binder-protein, og at man efter reaktionen bestemmer enzymaktiviteten i den flydende eller den faste fase af 3Q reaktionsblandingen. 1
2 Fremgangsmåde ifølge krav 1, kendetegnet ved, at man tilsætter de uopløselige antistoffer over for det specifikke binder-protein til reaktionsblandingen som det sidste reagens. 35 2 Fremgangsmåde ifølge krav 2 til bestemmelse af det bindelige stof, kendetegnet ved, at man først til prøven sætter det specifikke binder-protein og derpå enzymconjugatet og til sidst de uopløselige antistoffer over for det specifikke binder-
DK639871A 1970-12-28 1971-12-28 Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stof ved enzym-immunoanalyse DK150690C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL707018838A NL154599B (nl) 1970-12-28 1970-12-28 Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
NL7018838 1970-12-28

Publications (2)

Publication Number Publication Date
DK150690B true DK150690B (da) 1987-05-25
DK150690C DK150690C (da) 1988-06-06

Family

ID=19811894

Family Applications (1)

Application Number Title Priority Date Filing Date
DK639871A DK150690C (da) 1970-12-28 1971-12-28 Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stof ved enzym-immunoanalyse

Country Status (20)

Country Link
US (1) US3839153A (da)
JP (3) JPS5834783B1 (da)
AT (1) AT320145B (da)
AU (1) AU467394B2 (da)
BE (1) BE777309A (da)
BR (1) BR7108553D0 (da)
CA (1) CA964560A (da)
CH (1) CH557030A (da)
DE (1) DE2164768B2 (da)
DK (1) DK150690C (da)
EG (1) EG11604A (da)
ES (1) ES398372A1 (da)
FI (1) FI54034C (da)
FR (1) FR2120835A5 (da)
GB (1) GB1348938A (da)
IL (1) IL38371A (da)
IT (1) IT965020B (da)
NL (1) NL154599B (da)
SE (1) SE398557B (da)
ZA (1) ZA718332B (da)

Families Citing this family (854)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE31006E (en) * 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
NL171930C (nl) * 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3790447A (en) * 1972-07-05 1974-02-05 Abbott Lab Streptococci diagnostic method
DE2333434C3 (de) * 1973-06-30 1978-04-06 Istvan D. Dr. 5024 Pulheim Bartos Verfahren zur Durchführung serologischer Untersuchungen nach dem Prinzip der Komplementbindungsreaktion und gebrauchsfertige Schnelltestpackung hierfür
US4239746A (en) * 1973-06-30 1980-12-16 Dezso Istvan Bartos Complement fixation test employing reactants in a disposable package
US3935074A (en) * 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
GB1508132A (en) * 1974-05-20 1978-04-19 Technicon Instr Analysis of biological fluids
US4040907A (en) * 1974-06-20 1977-08-09 Syva Company Iodothyronine enzyme conjugates
US4001087A (en) * 1974-10-10 1977-01-04 The United States Of America Affinity labelling enzymes with esters of aromatic sulfonic acids
FR2288312A1 (fr) * 1974-10-14 1976-05-14 Pasteur Institut Procede de dosage immunoenzymatique de la progesterone
US4002532A (en) * 1974-10-21 1977-01-11 Weltman Joel K Enzyme conjugates
SE388694B (sv) * 1975-01-27 1976-10-11 Kabi Ab Sett att pavisa ett antigen exv i prov av kroppvetskor, med utnyttjande av till porost berarmaterial bundna eller adsorberande antikroppar
NL7501215A (nl) * 1975-02-01 1976-08-03 Akzo Nv Methode voor het aantonen en bepalen van een antigeen of antilichaam.
US4629688A (en) * 1975-04-28 1986-12-16 Miles Laboratories, Inc. Homogeneous specific binding assay method
US4230797A (en) * 1975-04-28 1980-10-28 Miles Laboratories, Inc. Heterogenous specific binding assay employing a coenzyme as label
USRE32696E (en) * 1975-09-04 1988-06-14 Akzona Incorporated Enzymatic immunological method for determination of antigens and antibodies
US4474878A (en) * 1975-09-29 1984-10-02 Cordis Laboratories, Inc. Sandwich EIA for antigen associated with hepatitis
US4642285A (en) * 1975-09-29 1987-02-10 Diamedix Corporation Sandwich EIA for antigen
SE7610683L (sv) * 1975-09-29 1977-06-10 Cordis Corp Metod for bestemning av nervaron av ett antigen associerat med hepatit
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
US4045384A (en) * 1976-07-23 1977-08-30 The Dow Chemical Company Method for forming an amide bond between a latex and protein
GB1549069A (en) * 1976-12-10 1979-08-01 Erba Farmitalia Enzyme linked immunoassay
US4200690A (en) * 1976-12-16 1980-04-29 Millipore Corporation Immunoassay with membrane immobilized antibody
US4407943A (en) * 1976-12-16 1983-10-04 Millipore Corporation Immobilized antibody or antigen for immunoassay
JPS5399319A (en) * 1977-02-09 1978-08-30 Hidematsu Hirai Novel qualitative and quantitative detecting method and detecting body for antgenic substance
IT1114861B (it) * 1977-05-12 1986-01-27 Sclavo Inst Sieroterapeut Metodo per la determinazione del contenuto di costituenti di fluidi biologici e mezzi adatti allo scopo
AU531777B2 (en) * 1978-04-05 1983-09-08 Syva Co. Label/solid conjugate immunoassay system
US4233402A (en) * 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4492751A (en) * 1978-04-10 1985-01-08 Miles Laboratories, Inc. Heterogenous specific binding assay employing an enzyme substrate as label
US4318980A (en) * 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US5605800A (en) * 1978-04-13 1997-02-25 Institut Pasteur Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
FR2422956A1 (fr) * 1978-04-13 1979-11-09 Pasteur Institut Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede
JPS5510590A (en) * 1978-05-04 1980-01-25 Wellcome Found Enzyme immunity quantity analysis
JPS5539702A (en) * 1978-08-30 1980-03-19 Takeda Chem Ind Ltd Method of measuring enzyme immunity of pancreas glucagon
FR2440555A1 (fr) * 1978-10-31 1980-05-30 Maes Roland Perfectionnements aux procedes de determination de substances montrant entre elles des affinites de liaison specifiques, par des tests faisant intervenir une phase solide
US4260678A (en) * 1979-02-23 1981-04-07 Corning Glass Works Determining creatine kinase isoenzmes via immobilized antibody-isoenzyme complexes
JPS55152459A (en) * 1979-05-18 1980-11-27 Yamasa Shoyu Co Ltd Method and reagent for measuring quantity of cyclic nucleotide
US4289748A (en) * 1979-05-31 1981-09-15 United States Of America Ultrasensitive enzymatic radioimmunoassay method
DE2930706A1 (de) * 1979-07-28 1981-02-05 Medac Klinische Spezialpraep Verfahren zum nachweis von erregerspezifischen antikoerpern
US4299916A (en) * 1979-12-26 1981-11-10 Syva Company Preferential signal production on a surface in immunoassays
US4394391A (en) * 1980-02-19 1983-07-19 Thorell Jan Ivan Radioimmunoassay reagents
US4322495A (en) * 1980-03-11 1982-03-30 Minnesota Mining And Manufacturing Co. Immunoassay
SE8003732L (sv) * 1980-05-19 1981-11-20 Pharmacia Diagnostics Ab Sett vid bestemningsmetoder involverande biospecifika affinitetsreaktioner
EP0040728A1 (en) * 1980-05-19 1981-12-02 Pharmacia Diagnostics Ab An improvement in and relating to assaying methods involving biospecific affinity reactions
JPS5714748A (en) * 1980-07-01 1982-01-26 Dainippon Pharmaceut Co Ltd Kit for quantitative determination of valproic acid and its method for quantitative determination
US4323647A (en) * 1980-10-15 1982-04-06 University Of Miami Steric hindrance enzyme immunoassay
DE3048884A1 (de) * 1980-12-23 1982-07-15 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur enzymimmunobestimmung in heterogener phase
ES8307897A1 (es) * 1981-04-13 1983-08-01 Hoechst Co American Un metodo de determinar la presencia de un antigeno en un medio liquido sospechoso de contenerlo.
US4604365A (en) * 1981-06-02 1986-08-05 Electro-Nucleonics, Inc. Immunoprecipitation assay
WO1982004323A1 (en) * 1981-06-02 1982-12-09 O Neill Sean Immunoprecipitation assay
US4506009A (en) * 1982-03-30 1985-03-19 University Of California Heterogeneous immunoassay method
US4535057A (en) * 1982-07-26 1985-08-13 Amf Incorporated Immunoassay employing monoclonal herpes simplex antibody and biotin-avidin detection system
US4515890A (en) * 1982-11-08 1985-05-07 Abbott Laboratories Immunoassay of terminal deoxynucleotidyl transferase
US4650751A (en) * 1983-04-29 1987-03-17 Technicon Instruments Corporation Protected binding assay avoiding non-specific protein interference
US4778752A (en) * 1983-10-11 1988-10-18 Scripps Clinic And Research Foundation Receptors specific for hapten-modified self proteins
EP0229767B1 (en) * 1985-03-18 1990-09-26 Royal Free Hospital School Of Medicine Improvements relating to the detection of viruses and antibodies
JPS62148857A (ja) * 1985-12-24 1987-07-02 Toyo Soda Mfg Co Ltd 免疫測定用材料の製造方法
EP0247730A3 (en) * 1986-04-28 1989-04-12 Antibody Technology Limited Antibodies, their preparation and use and products containing them
DE3636724A1 (de) * 1986-10-29 1988-06-23 Joern Dr Med Kekow Enzymimmunoassay (elisa) zur insulinbestimmung im mikrotiterplattensystem
US6528292B1 (en) * 1987-05-29 2003-03-04 Aventis Pharmaceuticals Holdings Inc. Derivatized polystyrene and other polymer supports for spectroscopic studies
US5256372A (en) * 1987-11-06 1993-10-26 Idexx Corporation Dipstick test device including a removable filter assembly
US5374524A (en) * 1988-05-10 1994-12-20 E. I. Du Pont De Nemours And Company Solution sandwich hybridization, capture and detection of amplified nucleic acids
US5137804A (en) * 1988-05-10 1992-08-11 E. I. Du Pont De Nemours And Company Assay device and immunoassay
US5614504A (en) * 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
US5965379A (en) * 1991-07-19 1999-10-12 Cytimmune Sciences Inc. Method for measuring endogenous cytokines
DE69230000T2 (de) * 1991-07-19 2000-05-11 Cytimmune Sciences, Inc. Verfahren und testsatz zur messung von endogenen zytokinen
US5464749A (en) 1991-07-22 1995-11-07 Bayer Corporation Immunoassay of free substances in biological fluids
US5874423A (en) * 1992-09-10 1999-02-23 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Digitalis-like compounds
US5637467A (en) * 1992-10-13 1997-06-10 Behringwerke Ag Heterogeneous assay using a pendulous drop
AU2635295A (en) * 1994-06-13 1996-01-05 Henry Ford Health System A novel neuronal-neonatal gene: neuronatin
US5843673A (en) * 1994-10-25 1998-12-01 Curators Of The University Of Missouri Method of screening for endometriosis
US6531277B2 (en) 1994-10-25 2003-03-11 The Curators Of The University Of Missouri Endometriosis-specific secretory protein
US20030152909A1 (en) * 1994-11-16 2003-08-14 Mitrani Eduardo N. In vitro micro-organs, and uses related thereto
US5607565A (en) * 1995-03-27 1997-03-04 Coulter Corporation Apparatus for measuring analytes in a fluid sample
US5777093A (en) * 1995-05-16 1998-07-07 Ramot-University Authority For Applied Research & Industrial Development Ltd. cDNAs associated with ataxia-telangiectasia
US5728807A (en) * 1995-05-16 1998-03-17 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Mutated proteins associated with ataxia-telangiectasia
US5858661A (en) 1995-05-16 1999-01-12 Ramot-University Authority For Applied Research And Industrial Development Ataxia-telangiectasia gene and its genomic organization
US6096508A (en) * 1995-08-16 2000-08-01 Kirkegaard & Perry Laboratoies, Inc. Method of reducing background in biotin-based assays
US5840322A (en) * 1996-12-19 1998-11-24 Ramot-University Authority For Applied Research & Industrial Devel. Ltd. Anti-oral-microbial adhesion fraction derived from vaccinium
EP1015471A1 (en) * 1997-08-21 2000-07-05 Quark Biotech, Inc. Hypoxia-regulated genes
US7973156B2 (en) 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
US6284496B1 (en) 1997-10-03 2001-09-04 University Of South Florida DNA vector for determining the presence of out-of-reading-frame mutations
EP1027453A4 (en) 1997-10-17 2004-12-01 Univ South Florida METHOD FOR DIAGNOSING AND MONITORING CELLULAR IMMUNE DEFICIENCIES
US7687057B2 (en) 1998-01-09 2010-03-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs, and uses related thereto
US20080206206A1 (en) 1998-05-07 2008-08-28 University Of South Florida Bone marrow-derived neuronal cells
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
US7605149B1 (en) 1998-07-13 2009-10-20 University Of South Florida Modulation of the phospholipase A2 pathway as a therapeutic
US6187563B1 (en) 1998-08-07 2001-02-13 Yale University βIV-spectrin-polypeptides and nucleic acids encoding same
JP2003523166A (ja) 1998-09-29 2003-08-05 ガミダ セル リミテッド 幹細胞および前駆細胞の増殖と分化を制御する方法
AU759719B2 (en) * 1999-02-04 2003-04-17 Pluristem Ltd. Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
US6440682B1 (en) * 1999-05-28 2002-08-27 Detroit R&D Inc. Detection of hypertension using immunoreactive metabolic products
US6787318B1 (en) * 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US7534605B2 (en) 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US20060127366A1 (en) * 1999-06-25 2006-06-15 Mitrani Eduardo N Method and device for inducing biological processes by micro-organs
CN1420933A (zh) * 1999-06-25 2003-05-28 耶路撒冷希伯来大学伊森姆研究发展公司 应用微器官诱导血管生成的方法
US6875582B1 (en) 1999-08-19 2005-04-05 Omniscience Pharmaceuticals, Inc. Methods and targets of antibiotic resistance
US7811981B2 (en) 1999-08-30 2010-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
US7101839B1 (en) 1999-08-30 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
ES2272333T3 (es) 1999-11-19 2007-05-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Procedimiento para aumentar el nivel de una sustancia de fermentacion.
US6544506B2 (en) * 2000-01-05 2003-04-08 Yeda Research & Development Co. Ltd. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
AU2001225441A1 (en) * 2000-01-24 2001-07-31 Agricultural Research Organization The Volcani Center Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
AU785493B2 (en) 2000-03-27 2008-01-03 Technion Research & Development Foundation Ltd. Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL135884A (en) * 2000-04-30 2005-08-31 Yissum Res Dev Co Method for measuring non-transferrin bound iron
HUP0300810A2 (hu) 2000-07-20 2003-08-28 M.G.V.S. Ltd. Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
PT2078531E (pt) 2000-08-08 2012-08-06 Technion Res & Dev Foundation Composições farmacêuticas e métodos úteis para modular a angiogénese
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
EP1683874A3 (en) 2000-08-29 2006-10-11 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents
WO2002026191A2 (en) * 2000-09-28 2002-04-04 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US7632522B2 (en) 2000-09-28 2009-12-15 Nanocyte Inc. Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US20070281037A9 (en) * 2000-09-28 2007-12-06 Nanocyte Inc. Sterile preparations and compositions including stinging capsules and methods of producing and using same
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
ES2338529T3 (es) 2000-11-17 2010-05-10 Vascular Biogenics Ltd. Prometores que exiben especificidad por celulas endoteliales y metodos para su utilizacion.
CA2429817C (en) 2000-11-24 2013-02-12 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US20040052769A1 (en) * 2000-11-30 2004-03-18 Yair Reisner Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
WO2002044736A2 (en) 2000-11-30 2002-06-06 Molecular Skincare Limited Diagnosis and treatment of epidermal or skin diseases
US20020142287A1 (en) * 2000-12-14 2002-10-03 Hirotaka Yamamoto High throughput assay to detect inhibitors of the map kinase pathway
US7087395B1 (en) 2001-01-16 2006-08-08 Quest Diagnostics Investments Incorporated Vitamin D assay
IL157006A0 (en) * 2001-01-17 2004-02-08 Univ Ramot Chitinases, derived from carnivorous plants, polynucleotide sequence encoding thereof, and methods of isolating and using same
CA2475021A1 (en) * 2001-01-31 2002-08-08 Dror Mevorach Induction of tolerance by apoptotic and/or necrotic cells
US20050202098A1 (en) * 2001-01-31 2005-09-15 Tolaren Disease therapy using dying or dead cells
US20030003454A1 (en) 2001-03-23 2003-01-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
WO2003008534A2 (en) * 2001-07-19 2003-01-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Polypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof
CA2458640A1 (en) 2001-08-16 2003-03-06 Bar-Ilan University Diagnosis, prevention and treatment of cancer
US7138144B2 (en) * 2001-09-07 2006-11-21 Nadir Askenasy Method of inducing immune tolerance via blood/lymph flow-restricted bone marrow transplantation
US20040136972A1 (en) 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
EP1436313B1 (en) 2001-10-19 2010-09-22 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
AUPR842501A0 (en) * 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
WO2003048298A2 (en) * 2001-12-05 2003-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof
US20050085432A1 (en) * 2001-12-26 2005-04-21 Aviva Lapidot Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (en) 2002-01-25 2006-06-07 Gamida Cell Ltd PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) * 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
WO2003078567A2 (en) * 2002-03-18 2003-09-25 Gamida-Cell Ltd. Methods of inducing differentiation in ex vivo expanded stem cells
IL164191A0 (en) * 2002-03-26 2005-12-18 Nanocyte Inc Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosme tic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue nanocyte inc.
US20040121442A1 (en) * 2002-05-05 2004-06-24 Ilan Chet Fungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof
EP2561889A3 (en) 2002-08-01 2013-04-03 Yeda Research and Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US7267981B2 (en) 2002-10-07 2007-09-11 Technion Research & Development Foundation Ltd. Human foreskin fibroblasts for culturing ES cells
AU2003284968A1 (en) * 2002-10-25 2004-05-13 University Of South Florida Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
EP2295980A1 (en) 2002-10-30 2011-03-16 Yissum Research Development Company, of The Hebrew University of Jerusalem Molecules and methods using same for measuring non-transferrin bound iron
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
WO2004050826A2 (en) * 2002-11-29 2004-06-17 Technion Research & Development Foundation Ltd. Method of dynamically culturing embryonic stem cells
US7491699B2 (en) * 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
DE60334846D1 (de) 2002-12-12 2010-12-16 R B T Rakuto Bio Technologies VERWENDUNG von LIGNINPEROXIDASE ZUR HAUT- UND HAARAUFHELLUNG
DK1572984T3 (da) 2002-12-16 2016-06-13 Technion Res & Dev Foundation Feedercellefrit, xenofrit dyrkningssystem til humane embryonale stamceller
AU2003288700B2 (en) 2003-01-02 2009-11-19 Rappaport Family Institute For Research In The Medical Sciences Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
ATE426575T1 (de) 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
US7786071B2 (en) 2003-03-04 2010-08-31 Yeda Research And Development Co. Ltd. Pon polypeptides polynucleotides encoding same and compositions and methods utilizing same
US20050054103A1 (en) * 2003-03-07 2005-03-10 Tony Peled Expansion of renewable stem cell populations using modulators of PI 3-kinase
US8017113B2 (en) 2003-03-12 2011-09-13 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
US7294701B2 (en) * 2003-04-02 2007-11-13 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
EP2330132B1 (en) 2003-04-04 2013-08-14 Yeda Research and Development Co. Ltd. Antibodies against MMP2 or MMP9 and pharmaceutical compositions containing same useful for inhibiting activity of said metalloproteins
EP1611233B1 (en) 2003-04-08 2016-01-06 Yeda Research And Development Co., Ltd. Stem cells having increased sensitivity to sdf-1 and methods of generating and using same
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
BR122016024209B1 (pt) 2003-05-22 2019-08-20 Evogene Ltd. Método para aumentar a biomassa e/ou tolerância de uma planta ao estresse salino e construto de ácido nucleico
AU2005234725B2 (en) 2003-05-22 2012-02-23 Evogene Ltd. Methods of Increasing Abiotic Stress Tolerance and/or Biomass in Plants and Plants Generated Thereby
US7554007B2 (en) 2003-05-22 2009-06-30 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants
US20050020499A1 (en) * 2003-05-27 2005-01-27 Bar Ilan University Methods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method
US8129514B2 (en) * 2003-06-19 2012-03-06 Evogene Ltd. Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
EP1636333A4 (en) * 2003-06-19 2007-10-24 Evogene Ltd NUCLEOTIDE SEQUENCES FOR REGULATING GENE EXPRESSION IN VEGETABLE TRICHROMES, AND HYBRID GENES AND METHODS IN WHICH THEY INTERVENE
KR101215821B1 (ko) 2003-06-30 2012-12-28 텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피. 아밀로이드 관련 질환을 진단 및 처치하기 위한 펩타이드, 그것에 대한 항체, 및 그 사용방법
EP1654348A4 (en) * 2003-08-14 2008-02-13 Bio Balance Corp BACTERIAL STRAINS, COMPOSITIONS AND PROBIOTIC USE THEREOF
US7625707B2 (en) 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
DK1678209T3 (da) 2003-10-07 2011-06-27 Yeda Res & Dev Antistoffer mod nik, deres frembringelse samt anvendelse
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
CA2542221A1 (en) * 2003-10-23 2005-05-06 Pfizer Products Inc. Vaccine for periodontal disease
CA2547459C (en) 2003-11-30 2013-10-08 Yeda Research And Development Co. Ltd Modulators of nik-siva complex formation for treating immune disorders
WO2005059100A2 (en) * 2003-12-12 2005-06-30 New York University Methods and compositions relating to cystatin c
US20100221233A1 (en) * 2003-12-15 2010-09-02 University Of South Florida Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
WO2005061018A1 (en) 2003-12-22 2005-07-07 Regentis Biomaterials Ltd. Matrix comprising naturally-occurring protein backbone
US8007847B2 (en) 2004-01-13 2011-08-30 Eytan Biderman Feeding formula appliance
US7423139B2 (en) * 2004-01-20 2008-09-09 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5′-UTR
EP1713900A4 (en) * 2004-01-27 2009-06-17 Compugen Ltd METHOD AND SYSTEMS FOR COMMENTING BIOMOLECULAR SEQUENCES
EP3006039B1 (en) 2004-03-02 2021-01-06 Acceleron Pharma Inc. Alk7 polypeptides for use in promoting fat loss
US8352031B2 (en) 2004-03-10 2013-01-08 Impulse Dynamics Nv Protein activity modification
CN101948846A (zh) 2004-06-14 2011-01-19 伊沃基因有限公司 参与植物纤维发育的多核苷酸和多肽和使用它们的方法
US8680062B2 (en) * 2004-07-06 2014-03-25 Deliversir Ltd. System for delivering therapeutic agents into living cells and cells nuclei
US20090156471A1 (en) * 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
WO2006030442A2 (en) 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US8000900B2 (en) 2004-09-21 2011-08-16 Microsoft Corporation Association-based predictions of pathogen characteristics
US20060095241A1 (en) * 2004-10-29 2006-05-04 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
EP1809751B1 (en) 2004-09-29 2010-09-01 CollPlant Ltd. Collagen producing plants and methods of generating and using same
ES2524601T3 (es) * 2004-09-29 2014-12-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. RNasa T2 humana recombinante y usos de la misma
WO2006040765A1 (en) * 2004-10-12 2006-04-20 Closed Loop Therapies Ltd. Methods and implantable devices for treating supraventricular arrhythmias
US8478535B2 (en) 2004-10-29 2013-07-02 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20060134680A1 (en) * 2004-12-22 2006-06-22 Alexander Kotlyar Homogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof
EP1844403A4 (en) 2005-01-16 2010-06-23 Zlango Ltd SIGNS COMMUNICATION
WO2006075335A2 (en) * 2005-01-16 2006-07-20 Zlango Ltd. Communications network system and methods for using same
US8019818B2 (en) * 2005-01-18 2011-09-13 Zlango Ltd. Communications network system and methods for using same
EP1843850B1 (en) 2005-01-31 2015-11-18 Realbio Technologies Ltd. Multistep reaction lateral flow capillary device
ES2366654T3 (es) 2005-02-17 2011-10-24 HADASIT MEDICAL RESEARCH SERVICES &amp; DEVELOPMENT CO., LTD. Biofosfonatos para tratar la endometriosis.
JP5432455B2 (ja) 2005-02-25 2014-03-05 ザ ステート オブ イスラエル、ミニストリー オブ アグリカルチャー アンド ルーラル ディベロップメント、アグリカルチュラル リサーチ オーガナイゼイション、(エー.アール.オー.)、ボルカニ センター 炎症治療用の果実細胞培養抽出物
US7695927B2 (en) * 2005-03-18 2010-04-13 Detroit R & D Detection of hypertension using glucuronidated metabolic products
US20090068207A1 (en) * 2005-04-15 2009-03-12 Vascular Biogenics Ltd. Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
US8834862B2 (en) * 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
WO2006116742A2 (en) * 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Fluorescent nanoparticles conjugated to antibodies via a peg linker
JP5628476B2 (ja) 2005-04-28 2014-11-19 ベンタナ・メデイカル・システムズ・インコーポレーテツド 抗体コンジュゲート
WO2006126208A2 (en) 2005-05-26 2006-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
EP2465924A3 (en) 2005-06-16 2013-01-02 Ramot at Tel-Aviv University Ltd. Isolated cells and populations comprising same for the treament of cns diseases
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
EP2487182B1 (en) 2005-07-07 2019-10-23 FULCRUM SP Ltd. Sp1 polypeptides, modified sp1 polypeptides and uses thereof
CA2614531C (en) 2005-07-07 2015-06-16 Avraham Hochberg Nucleic acid agents for downregulating h19, and methods of using same
WO2007010533A2 (en) 2005-07-18 2007-01-25 Protalix Ltd. Mucosal or enteral administration of biologically active macromolecules
US7993657B2 (en) 2005-07-26 2011-08-09 University Of Medicine And Dentistry Of New Jersey Antibody profiles characteristic of tuberculosis state
US8642330B2 (en) * 2005-08-08 2014-02-04 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
EP1928479B1 (en) 2005-08-24 2016-06-08 Yeda Research And Development Co., Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
AU2006286149B2 (en) 2005-08-29 2012-09-13 Technion Research And Development Foundation Ltd. Media for culturing stem cells
JP2009508516A (ja) * 2005-09-22 2009-03-05 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 核酸構築物、薬剤組成物、及び癌治療のためのその使用方法
US20070087437A1 (en) * 2005-10-14 2007-04-19 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
MX350551B (es) 2005-10-24 2017-09-08 Evogene Ltd Polipeptidos aislados, polinucleotidos que los codifican, plantas transgenicas que expresan los mismos y metodos para usarlos.
JP4888387B2 (ja) * 2005-11-18 2012-02-29 三菱電機株式会社 エレベータのかご照明装置
JP5199880B2 (ja) * 2005-11-23 2013-05-15 ベンタナ・メデイカル・システムズ・インコーポレーテツド 分子コンジュゲート
CA2632288A1 (en) 2005-11-29 2007-06-07 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
EP2237037A1 (en) 2005-12-12 2010-10-06 Gyros Patent Ab Microfluidic device and use thereof
US20070134739A1 (en) * 2005-12-12 2007-06-14 Gyros Patent Ab Microfluidic assays and microfluidic devices
WO2007080559A2 (en) 2006-01-16 2007-07-19 Zlango Ltd. Iconic communication
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
WO2007092252A2 (en) 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
BRPI0706967A2 (pt) 2006-02-06 2011-04-12 Rappaport Family Inst For Res método e kit para diagnosticar dmt1
AU2007224386B2 (en) 2006-03-06 2013-12-19 Zetiq Technologies Ltd. Methods and compositions for identifying a cell phenotype
EP2366775B1 (en) 2006-03-23 2015-04-22 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2004858A4 (en) 2006-03-28 2009-12-09 Tel Hashomer Medical Res Infrastructure & Services Ltd METHOD AND KITS FOR DETERMINING AN INVESTMENT TO WARFARINE RESISTANCE
US8071323B2 (en) * 2006-04-07 2011-12-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies that bind human insulin like growth factors and their use
ES2549128T3 (es) * 2006-05-19 2015-10-23 Technion Research And Development Foundation Ltd. Proteínas de fusión, usos de las mismas y procesos para producir las mismas
US20070281883A1 (en) * 2006-06-05 2007-12-06 Hanna Rosenfeld Development of follicle stimulating hormone agonists and antagonists in fish
US8629259B2 (en) 2006-07-20 2014-01-14 Yeda Research And Development Co. Ltd. Photosynthetic organisms and compositions and methods of generating same
EP2064319B1 (en) 2006-08-28 2017-02-22 Yeda Research and Development Co. Ltd. Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns
US7888059B2 (en) * 2006-10-05 2011-02-15 Yeda Research And Development Co. Ltd. Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same
WO2008041183A2 (en) 2006-10-05 2008-04-10 Technion Research & Development Foundation Ltd. Microtubes and methods of producing same
MX349479B (es) * 2006-12-20 2017-07-31 Evogene Ltd Polinucleotidos y polipeptidos involucrados en el desarrollo de fibra vegetal y metodos de uso.
EP2111449B1 (en) * 2007-01-16 2012-03-07 Yissum Research Development Company of the Hebrew University of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
WO2008093331A1 (en) * 2007-01-29 2008-08-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antibody conjugates for circumventing multi-drug resistance
US8911996B2 (en) 2007-01-31 2014-12-16 Technion Research & Development Foundation Limited Electrospun scaffolds and methods of generating and using same
EP2125050B1 (en) 2007-02-01 2014-07-30 Technion Research & Development Foundation Ltd. Albumin fibers and fabrics and methods of generating and using same
WO2008104979A2 (en) 2007-02-28 2008-09-04 Yeda Research And Development Co. Ltd. Nuclear targeting sequences
CA2682093A1 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
JP2010523104A (ja) 2007-04-02 2010-07-15 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ガン細胞検出方法ならびにガン疾患の診断およびガン疾患の処置のモニタリングのためのその使用
MX2009010858A (es) 2007-04-09 2009-11-02 Evogene Ltd Polinucleotidos, polipeptidos y metodos para aumentar el contenido de aceite, la velocidad de crecimiento y biomasa de las plantas.
WO2014064687A1 (en) 2012-10-22 2014-05-01 Deliversir Ltd A system for delivering therapeutic agents into living cells and cells nuclei
US9156865B2 (en) 2007-04-23 2015-10-13 Deliversir Ltd System for delivering therapeutic agents into living cells and cells nuclei
EP2144633B1 (en) * 2007-04-23 2014-07-16 Deliversir Ltd A system for delivering therapeutic agents into living cells and cells nuclei
US9556210B2 (en) 2007-04-23 2017-01-31 Sabag-Rfa Ltd. System for delivering therapeutic agents into living cells and cells nuclei
EP2152905B1 (en) 2007-05-01 2015-12-02 Tel Hashomer Medical Research Infrastructure and Services Ltd. Methods and kits for detecting fetal cells in the maternal blood
CA2685954A1 (en) 2007-05-03 2008-11-13 Agency For Science, Technology And Research Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
CA2685701C (en) 2007-05-07 2019-01-15 Protalix Ltd. Large scale disposable bioreactor
ATE540115T1 (de) 2007-07-11 2012-01-15 Yeda Res & Dev Nukleinsäurekonstruktsysteme mit fähigkeit zur diagnose oder behandlung eines zellzustands
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
JP2010533705A (ja) 2007-07-15 2010-10-28 ヒルマン,イチャク 抗菌ペプチドまたはその阻害剤を用いた疾病治療
BR122020022203B1 (pt) 2007-07-24 2021-04-20 Evogene Ltd método de aumento da taxa de crescimento de uma planta
SI2185198T1 (sl) 2007-08-02 2015-04-30 Gilead Biologics, Inc. Inhibitorji LOX in LOXL2 ter njihova uporaba
BRPI0814479A2 (pt) 2007-08-15 2016-07-12 Yeda Res & Dev "método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica"
AU2008299318A1 (en) 2007-09-12 2009-03-19 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating tumors in immune-privileged sites
BRPI0815946B8 (pt) 2007-09-19 2021-05-25 Pluristem Ltd artigo de fabricação
ES2620487T3 (es) 2007-10-19 2017-06-28 Rappaport Family Institute For Research In The Medical Sciences Composiciones que comprenden semaforinas para uso en el tratamiento del cáncer
EP2599790A1 (en) 2007-11-26 2013-06-05 Yissum Research Development Company of The Hebrew University of Jerusalem Compositions comprising fibrous polypeptides and polysachharides
CN101977928B (zh) 2007-12-27 2014-12-10 伊沃基因有限公司 用于改进植物的水分利用效率、肥料利用效率、生物/非生物胁迫耐受性、产量和生物量的分离多肽、多核苷酸
EP2245055A2 (en) * 2008-01-31 2010-11-03 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US9297094B2 (en) 2008-02-21 2016-03-29 Technion Research & Development Foundation Ltd. Use of electrospun microtubes for drug delivery
US20110033473A1 (en) * 2008-04-09 2011-02-10 Yoram Reiter Anti influenza antibodies and uses thereof
US8747855B2 (en) * 2008-04-09 2014-06-10 Technion Research & Development Foundation Limited Anti human immunodeficiency antibodies and uses thereof
CN102083615B (zh) * 2008-04-10 2014-08-13 战略系统有限公司 用于三维模型打印的系统和方法
CN104491845A (zh) 2008-04-18 2015-04-08 科尔普兰特有限公司 产生和使用原胶原的方法
MX2010011511A (es) 2008-04-21 2011-06-09 Danziger Innovations Ltd Vectores de expresion viral de planta y uso de los mismos para generar variaciones genotipicas en genomas de plantas.
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
CA3148194A1 (en) 2008-05-22 2009-11-26 Evogene Ltd. Isolated polynucleotides and peptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
US9393273B2 (en) 2008-05-27 2016-07-19 Pluristem Ltd. Methods of treating inflammatory colon diseases
EP3514229A1 (en) 2008-05-28 2019-07-24 Ramot at Tel-Aviv University Ltd. Mesenchymal stem cells for the treatment of cns diseases
CN102076415B (zh) 2008-06-29 2015-06-24 瑞尔比奥技术有限公司 尤其可用作生物测定过程中的捕捉装置的液体转移装置
JP5756014B2 (ja) 2008-08-08 2015-07-29 エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ(エイ・スター) がんの診断および治療のためのvhz
WO2010017544A2 (en) 2008-08-08 2010-02-11 Genisphere, Inc. Long-acting dna dendrimers and methods thereof
BRPI0912898B1 (pt) 2008-08-18 2022-04-12 Evogene Ltd Método para aumentar a eficiência de uso do nitrogênio e/ou tolerância à deficiência de nitrogênio de uma planta
CN105708862B (zh) 2008-09-02 2020-11-06 普拉里斯坦有限公司 来自胎盘组织的粘附细胞及其在治疗中的用途
US8367392B2 (en) * 2008-09-05 2013-02-05 Transalgae Ltd. Genetic transformation of algal and cyanobacteria cells by microporation
US20110305682A1 (en) 2008-09-11 2011-12-15 Ben Gurion University Of The Negev Research And Development Authority Compositions and Methods for Treating S. Pneumonia Infection
CN107595889A (zh) 2008-09-12 2018-01-19 克里奥普拉斯低温生物有限公司 缺血性组织的细胞疗法
JP5676451B2 (ja) 2008-09-24 2015-02-25 テル ハショメール メディカル リサーチ,インフラストラクチャ アンド サービシーズ リミテッド ペプチド
EP2342356A4 (en) 2008-09-29 2012-11-21 Univ Ben Gurion AMYLOID BETA PEPTIDASES AND METHOD OF USE THEREOF
EP2347014B1 (en) 2008-10-30 2016-09-21 Evogene Ltd. Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficieny
US20110229892A1 (en) 2008-11-17 2011-09-22 Yehuda G Assaraf Method for predicting a patient's responsiveness to anti-folate therapy
WO2010058396A1 (en) 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A cd44vra antibody and diagnostic and therapeutic methods using same
WO2010061383A1 (en) 2008-11-26 2010-06-03 Biodalia Microbiological Technologies Ltd. A method of in-situ enrichment of foods with fructan
WO2010064231A1 (en) 2008-12-02 2010-06-10 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of analyzing a-i rna editing and nucleic acid constructs capable of same
WO2010064247A1 (en) 2008-12-03 2010-06-10 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for determining predisposition to cancer
US8734759B2 (en) 2008-12-05 2014-05-27 Yeda Research And Development Co. Ltd. Methods of diagnosing and treating motor neuron diseases
WO2010071610A1 (en) 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
EP2376653A2 (en) 2008-12-29 2011-10-19 Yissum Research Development Company of The Hebrew University of Jerusalem Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
MX340023B (es) 2008-12-29 2016-06-22 Evogene Ltd Polinucleotidos, polipeptidos codificados, y metodos para utilizarlos para aumentar la tolerancia al estres abiotico, biomasa y/o rendimiento en plantas que los expresan.
SG10201504379VA (en) 2008-12-29 2015-07-30 Tel Hashomer Medical Res Infrastructure & Services Ltd Peptides and compositions for prevention of cell adhesion and methods of using same
WO2010076794A1 (en) 2008-12-31 2010-07-08 Technion Research & Development Foundation Ltd. Method of denitrifying brine and systems capable of same
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
IL196820A0 (en) 2009-02-01 2009-11-18 Yissum Res Dev Co Devitalized, acellular scaffold matrices derived from micro-organs seeded with various cells
EP2391377A2 (en) 2009-02-02 2011-12-07 Ramot at Tel-Aviv University Ltd. Peptides, pharmaceutical compositions comprising same and uses thereof
WO2010089707A1 (en) 2009-02-04 2010-08-12 Yeda Research And Development Co. Ltd. Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
EP2401362B1 (en) 2009-02-26 2017-04-12 Tel HaShomer Medical Research Infrastructure and Services Ltd. Isolated populations of renal stem cells and methods of isolating and using same
CA3123543A1 (en) 2009-03-02 2010-09-10 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
PL2406279T3 (pl) 2009-03-09 2016-07-29 Univ Ramot Kompozycje do zapobiegania i leczenia chorób neurodegeneratywnych.
WO2010103517A1 (en) 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
WO2010113096A1 (en) 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
EP2344179A1 (en) 2009-04-01 2011-07-20 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center A method of regulating proliferation and differentiation of keratinocyes
WO2010116375A1 (en) 2009-04-08 2010-10-14 Yeda Research And Development Co. Ltd. Isolated peptides for regulating apoptosis
DK2424896T3 (da) 2009-04-30 2015-12-14 Tel Hashomer Medical Res Infrastructure & Services Ltd Anti-CEACAM1-antistoffer og fremgangsmåder til anvendelse deraf
WO2010134073A1 (en) 2009-05-19 2010-11-25 Zetiq Technologies Ltd. Kits for and methods of differential staining of cervical cancer cells and/or tissues
WO2010137013A1 (en) 2009-05-27 2010-12-02 Ramot At Tel Aviv University Ltd. Crystallized photosystem i units from the pea plant and their use in solid state devices
US20120078163A1 (en) 2009-05-27 2012-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of generating connective tissue
WO2010137017A2 (en) 2009-05-27 2010-12-02 Yeda Research And Development Co. Ltd. Proteasome inhibitors and uses thereof
EP2435078A1 (en) 2009-05-28 2012-04-04 Yeda Research and Development Co. Ltd. Methods of treating inflammation
EP2440033B1 (en) 2009-06-10 2017-03-15 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
IN2012DN00715A (da) 2009-06-24 2015-06-19 Health Corp Rambam
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
WO2011004379A1 (en) 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer
CA2768725A1 (en) 2009-07-21 2011-01-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. A method of diagnosing cancer
GB0913442D0 (en) 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
WO2011021194A2 (en) 2009-08-17 2011-02-24 Technion Research & Development Foundation Ltd. Pericyte progenitor cells and methods of generating and using same
AU2010284000A1 (en) * 2009-08-21 2012-03-22 Gilead Biologics, Inc. In vitro screening assays
US20120157512A1 (en) 2009-08-21 2012-06-21 Monsanto Technology Llc Preventing and Curing Beneficial Insect Diseases Via Plant Transcribed Molecules
SG2014004816A (en) 2009-08-21 2014-03-28 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
CN106619515A (zh) 2009-08-27 2017-05-10 工业研究与发展基金会有限公司 脂质体组合物及其用途
US9610331B2 (en) 2009-09-08 2017-04-04 Yeda Research And Development Co. Ltd. Methods for hematopoietic precursor mobilization
EP2475784A1 (en) 2009-09-08 2012-07-18 Ramot at Tel-Aviv University Ltd. Methods of diagnosing amyotrophic lateral sclerosis (als)
US20120171213A1 (en) 2009-09-10 2012-07-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
US8212001B2 (en) 2009-09-17 2012-07-03 Ramot At Tel-Aviv University Ltd. Peptides for the treatment of oxidative stress related disorders
US8735124B2 (en) 2009-09-17 2014-05-27 Yeda Research And Development Co. Ltd. Isolated PON1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2011033506A2 (en) 2009-09-17 2011-03-24 Yeda Research And Development Co. Ltd. Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
US20110081706A1 (en) * 2009-10-02 2011-04-07 TransAlgae Ltd Method and system for efficient harvesting of microalgae and cyanobacteria
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
CA2777448C (en) 2009-10-14 2023-02-28 Ilan Sela Compositions for controlling varroa mites in bees
EP2488209B1 (en) 2009-10-16 2016-09-28 Rutgers, the State University of New Jersey Method for treating chronic nerve tissue injury using a cell therapy strategy
WO2011048600A1 (en) 2009-10-21 2011-04-28 Danziger Innovations Ltd. Generating genotypic variations in plant genomes by gamete infection
IL201999A (en) 2009-11-08 2017-10-31 Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel A knockout mouse of the 1 – mo gene, a gene associated with morbidly extreme obesity
WO2011058555A1 (en) 2009-11-12 2011-05-19 Yeda Research And Development Co. Ltd. A method of editing dna in a cell and constructs capable of same
CA3174901A1 (en) 2009-11-12 2011-05-19 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
EP2498806B1 (en) 2009-11-12 2014-12-31 Ramot at Tel-Aviv University Ltd. Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes
US20120230974A1 (en) 2009-11-17 2012-09-13 Protalix Ltd Alkaline alpha galactosidase for the treatment of fabry disease
EP2504472A1 (en) 2009-11-24 2012-10-03 Collplant Ltd. Method of generating collagen fibers
AU2010322808B9 (en) 2009-11-30 2014-08-07 Pluri Biotech Ltd Adherent cells from placenta and use of same in disease treatment
WO2011067745A2 (en) 2009-12-06 2011-06-09 Rosetta Green Ltd. Compositions and methods for enhancing plants resistance to abiotic stress
US8778904B2 (en) 2009-12-09 2014-07-15 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the CNS
EP2519097B1 (en) 2009-12-28 2016-03-02 Evogene Ltd. Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
DK3184109T3 (da) 2009-12-29 2021-02-15 Gamida Cell Ltd Fremgangsmåder til forbedring af natural killer-cellers proliferation og aktivitet
AU2011204405B2 (en) 2010-01-05 2015-06-18 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
WO2011086509A1 (en) 2010-01-12 2011-07-21 Vascular Biogenics Ltd. Methods of producing adenovirus vectors and viral preparations generated thereby
CN102822202B (zh) 2010-01-27 2015-07-22 耶达研究及发展有限公司 抑制金属蛋白的抗体
CA2789022A1 (en) 2010-02-04 2011-08-11 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
WO2011099006A2 (en) 2010-02-11 2011-08-18 Yeda Research And Development Co. Ltd. Enzymatic systems for carbon fixation and methods of generating same
WO2011104708A2 (en) 2010-02-24 2011-09-01 Ben Gurion University Of The Negev Research And Development Authority Methods for inhibiting necrosis
WO2011107939A1 (en) 2010-03-01 2011-09-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting efficacy of an anti-vegfa treatment for solid tumors
WO2011107994A1 (en) 2010-03-04 2011-09-09 Yeda Research And Development Co. Ltd. Methods of measuring protein stability
EP2545176B1 (en) 2010-03-08 2016-05-11 Yeda Research and Development Co. Ltd. Recombinant protein production in heterologous systems
WO2011112570A1 (en) 2010-03-08 2011-09-15 Monsanto Technology Llc Polynucleotide molecules for gene regulation in plants
US20120329089A1 (en) 2010-03-11 2012-12-27 Jacob Edrei Methods of generating hydrogen
WO2011125015A2 (en) 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
WO2011128895A2 (en) 2010-04-12 2011-10-20 Ben Gurion University Of The Negev Research And Development Authority Sulfotransferase of a red microalga and uses thereof
US8927274B2 (en) 2010-04-12 2015-01-06 Technion Research & Development Foundation Limited Populations of pancreatic progenitor cells and methods of isolating and using same
EP2561356B1 (en) 2010-04-18 2016-08-03 Yeda Research and Development Co. Ltd. MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
AU2011246876B2 (en) 2010-04-28 2016-06-23 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics
US20130053277A1 (en) 2010-05-04 2013-02-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of identifying inhibitors of polypeptides-of-interest
EP2566500B1 (en) 2010-05-05 2017-04-12 Rappaport Family Institute for Research in the Medical Sciences Ccl1 for use in therapy
IL208820A0 (en) 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
PL2569417T3 (pl) 2010-05-13 2018-12-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. Izolowane populacje dorosłych komórek nerkowych i sposoby ich izolowania i stosowania
DK2390664T3 (da) 2010-05-25 2013-07-22 Fraunhofer Ges Forschung Fremgangsmåde til elektrokemisk påvisning af bindingsreaktioner
CA2800257C (en) 2010-05-26 2019-03-05 The Board Of Trustees Of The University Of Illinois Personal glucose meters for detection and quantification of a broad range of analytes
EP2575859B1 (en) 2010-06-03 2018-09-19 Ramot at Tel Aviv University, Ltd. Methods of treating diabetes and compositions capable of same
CN102933723A (zh) 2010-06-07 2013-02-13 奥斯娜特·阿舒尔-费边 用于诊断与缺氧有关的病状的方法和试剂盒
WO2011158243A2 (en) 2010-06-16 2011-12-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of diagnosing and treating cancer
US20130097731A1 (en) 2010-06-16 2013-04-18 Futuragene Israel Ltd. Pest-resistant plants containing a combination of a spider toxin and a chitinase
EP2593468B1 (en) 2010-07-12 2020-06-10 The State of Israel, Ministry of Agriculture and Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center Isolated polynucleotides and methods and plants using same for regulating plant acidity
JP2013535963A (ja) 2010-07-15 2013-09-19 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド Mhcクラスiiと糖尿病関連自己抗原性ペプチドとの天然型複合体に対するt細胞受容体様特異性を有する単離された高親和性実体
JP2013538555A (ja) 2010-07-15 2013-10-17 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド Mhcクラスiiとグルタミン酸デカルボキシラーゼ(gad)自己抗原性ペプチドとの天然型複合体に対するt細胞受容体様特異性を有する単離された高親和性実体
BR112013000984A2 (pt) 2010-07-15 2017-10-03 Technion Res & Dev Foundation Estrutura de ácido nucleico para o aumento da tolerância ao estresse abiótico em plantas
EP2595637B1 (en) 2010-07-22 2017-11-01 Cellect Biotherapeutics Ltd. Regulatory immune cells with enhanced targeted cell death effect
US9144585B2 (en) 2010-07-27 2015-09-29 Technion Research & Development Foundation Limited Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
WO2012014208A2 (en) 2010-07-27 2012-02-02 Yeda Research And Development Co. Ltd. Methods and systems for assessing clonality of cell cultures
US20130130387A1 (en) 2010-07-27 2013-05-23 Technion Research & Development Foundation Limited Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
EP2600885A2 (en) 2010-08-04 2013-06-12 Ramot at Tel Aviv University, Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
US9394523B2 (en) 2010-08-22 2016-07-19 Ramot At Tel-Aviv University Ltd. Induced pluripotent stem cells derived from human pancreatic beta cells
WO2012025925A1 (en) 2010-08-24 2012-03-01 Rappaport Family Institute For Research In The Medical Sciences Methods of improving transplantation using sdf-1alpha
BR112013004851A2 (pt) 2010-08-30 2016-06-07 Evogene Ltd método de aumento de eficiência do uso de nitrogênio, rendimento, biomassa, taxa de crescimento, vigor, conteúdo de óleo, rendimento da fibra e/ou tolerância ao estresse abiótico de uma planta, polinucleotídeo isolado, estrutura de ácido nucleio, polipeptídeo isolado, célula vegetal e planta transgêncica
US20130164288A1 (en) 2010-09-07 2013-06-27 Protalix Ltd. Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
CA3150342A1 (en) 2010-09-07 2012-03-15 Technion Research & Development Foundation Limited Novel methods and culture media for culturing pluripotent stem cells
WO2012032510A1 (en) 2010-09-07 2012-03-15 Yeda Research And Development Co. Ltd. Primers for amplifying dna and methods of selecting same
WO2012032519A2 (en) 2010-09-07 2012-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of diagnosing parkinson's disease
EP2613801B1 (en) 2010-09-08 2016-06-08 Yeda Research and Development Co. Ltd. Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
EP2614083A2 (en) 2010-09-08 2013-07-17 Yeda Research and Development Co. Ltd An immunosuppressive drug combination for a stable and long term engraftment
CN103210082A (zh) 2010-09-15 2013-07-17 雷蒙特亚特特拉维夫大学有限公司 扩增胰岛β细胞和使其再分化的方法
US20130210901A1 (en) 2010-09-20 2013-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating neurodegenerative diseases
EP3075396A1 (en) 2010-10-17 2016-10-05 Yeda Research and Development Co. Ltd. Methods and compositions for the treatment of insulin-associated medical conditions
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
US20130216603A1 (en) 2010-10-27 2013-08-22 Nanocyte (Israel) Ltd. Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
ES2688457T3 (es) 2010-10-28 2018-11-02 Yeda Research And Development Co. Ltd. Métodos de generación de anticuerpos contra metaloenzimas
UY33705A (es) 2010-11-03 2012-04-30 Yissum Res Dev Co Plantas transgenicas con rendimientos de sacarificacion mejorados y metodos para generarlas
WO2012059925A2 (en) 2010-11-04 2012-05-10 Ben-Gurion University Of The Negev Research And Development Authority Acyl-coa: diacylglycerol acyltransferase 1-like gene (ptdgat1) and uses thereof
WO2012066549A1 (en) 2010-11-15 2012-05-24 Ramot At Tel-Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
EP2640404B1 (en) 2010-11-17 2017-02-22 Ben Gurion University of The Negev Research and Development Authority T-cell therapy to neurodegenerative diseases
JP6139410B2 (ja) 2010-12-02 2017-05-31 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド 角膜細胞の作製方法および該角膜細胞を含む細胞集団
US20120183960A1 (en) 2010-12-07 2012-07-19 Enterologics, Inc. Method for identifying e. coli m-17
US9404087B2 (en) 2010-12-15 2016-08-02 Kadimastem Ltd. Insulin producing cells derived from pluripotent stem cells
BR122021002248B1 (pt) 2010-12-22 2022-02-15 Evogene Ltd Método para aumentar a tolerância ao estresse abiótico, produção, biomassa, e/ou taxa de crescimento de uma planta
AU2011350620B2 (en) 2010-12-28 2017-03-02 Kamedis Ltd. Plant extracts for the treatment and prevention of infections
EP2665814B1 (en) 2011-01-20 2017-05-17 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2012104851A1 (en) 2011-01-31 2012-08-09 Yeda Research And Development Co. Ltd. Methods of diagnosing disease using overlap extension pcr
WO2012114339A1 (en) 2011-02-23 2012-08-30 Rappaport Family Institute For Research In The Medical Sciences High affinity molecules capable of binding a type a plexin receptor and uses of same
CN103597078B (zh) 2011-03-02 2016-12-14 富途锐基尼以色列有限公司 具有功能失调的t3ss蛋白的抗菌性转基因植物
WO2012117373A1 (en) 2011-03-03 2012-09-07 Ramot At Tel-Aviv University Ltd. Genetically modified muscle cells which express neurotrophic factors
CN103597073B (zh) 2011-03-06 2019-06-07 默克雪兰诺有限公司 低岩藻糖细胞系及其应用
WO2012120518A1 (en) 2011-03-08 2012-09-13 Ramot At Tel-Aviv University Ltd. Compositions and methods for diagnosing and treating phenylketonuria (pku)
EP2685976B1 (en) 2011-03-17 2017-12-27 Tel HaShomer Medical Research Infrastructure and Services Ltd. Quinolone analogs for treating autoimmune diseases
AU2012227883A1 (en) 2011-03-17 2013-10-24 Ramot At Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
KR101903339B1 (ko) 2011-03-22 2018-10-01 플루리스템 리미티드 방사선 또는 화학적 손상을 치료하는 방법
MX2013010910A (es) 2011-03-24 2014-03-27 Neurim Pharma 1991 Peptidos neuroprotectores.
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
WO2012137202A1 (en) 2011-04-05 2012-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci)
DK2694962T3 (da) 2011-04-06 2017-06-12 Ramot At Tel-Aviv Univ Ltd Fremgangsmåder til monitorering og analyse af profiler for metabolisk aktivitet samt diagnostiske og terapeutiske anvendelser deraf
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
WO2012140519A2 (en) 2011-04-15 2012-10-18 Pluristem Ltd. Methods and systems for harvesting cells
WO2012150598A2 (en) 2011-05-03 2012-11-08 Evogene Ltd. Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
WO2012150600A2 (en) 2011-05-04 2012-11-08 Ramot At Tel-Aviv University Ltd. Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease
WO2012153333A1 (en) 2011-05-09 2012-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Regeneration and repair of mesenchymal tissue using amelogenin
WO2012153336A2 (en) 2011-05-12 2012-11-15 Rakuto Bio Technologies Ltd. Methods and device for lightening skin complexion
WO2012156976A1 (en) 2011-05-16 2012-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of producing artemisinin in non-host plants and vectors for use in same
US20140088017A1 (en) 2011-05-23 2014-03-27 Yeda Research And Development Co., Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2012160526A2 (en) 2011-05-23 2012-11-29 Ofir Menashe Formulations of microorganism comprising particles and uses of same
SG10201604103SA (en) 2011-05-31 2016-07-28 Hutchison Biofilm Medical Solutions Ltd Dispersion and detachment of cell aggregates
US20140113376A1 (en) 2011-06-01 2014-04-24 Rotem Sorek Compositions and methods for downregulating prokaryotic genes
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
WO2012172555A1 (en) 2011-06-14 2012-12-20 Yeda Research And Development Co. Ltd. Combination therapy to prevent dcis formation and progression to breast cancer
AR086989A1 (es) 2011-06-23 2014-02-05 Kaiima Bio Agritech Ltd Trigo comun: sus plantas o partes que tienen un genoma parcial o completamente multiplicado, sus hibridos y productos y metodos para generarlos y utilizarlos
JP2014520567A (ja) 2011-07-20 2014-08-25 カイイマ バイオ アグリテック リミテッド 部分的多重ゲノムまたは完全多重ゲノムを有するトウモロコシ植物およびその使用
US20130030452A1 (en) 2011-07-27 2013-01-31 Health Corporation - Rambam Devices for surgical applications
BR112014002737B1 (pt) 2011-08-04 2022-08-02 Yeda Research And Development Co. Ltd. Mir-135
JP6063613B2 (ja) 2011-08-09 2017-01-18 イェダ リサーチ アンド デベロップメント カンパニー リミテッド ベータ細胞の分化およびインスリン産生を促進するためのmiR−7のダウンレギュレーション
WO2013024481A1 (en) 2011-08-14 2013-02-21 Kaiima Bio Agritech Ltd. Durum wheat plants having a partially or fully multiplied genome and uses thereof
WO2013035070A1 (en) 2011-09-07 2013-03-14 Yeda Research And Development Co. Ltd. Olfactory signature and odorant mixture having the same
WO2013035071A1 (en) 2011-09-08 2013-03-14 Yeda Research And Development Co. Ltd. Novel risk biomarkers for lung cancer
EP2753351B1 (en) 2011-09-08 2017-06-21 Yeda Research and Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
EP2755467B1 (en) 2011-09-13 2017-07-19 Monsanto Technology LLC Methods and compositions for weed control
UA116089C2 (uk) 2011-09-13 2018-02-12 Монсанто Текнолоджи Ллс Спосіб та композиція для боротьби з бур'янами (варіанти)
CN104160028A (zh) 2011-09-13 2014-11-19 孟山都技术公司 用于杂草控制的方法和组合物
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
EP3434780A1 (en) 2011-09-13 2019-01-30 Monsanto Technology LLC Methods and compositions for weed control
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
PL2768851T3 (pl) 2011-10-21 2018-05-30 Augurex Life Sciences Corp. Antygeny pochodzące z cytrulinowanego białka 14-3-3 oraz ich zastosowania w diagnozie reumatoidalnego zapalenia stawów
US9145559B2 (en) 2011-10-27 2015-09-29 Yeda Research And Development Co. Ltd. Methods of treating cancer
WO2013067076A2 (en) 2011-11-03 2013-05-10 Quark Pharmaceuticals, Inc. Methods and compositions for neuroprotection
WO2013070821A1 (en) 2011-11-08 2013-05-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
US9736998B2 (en) 2011-11-23 2017-08-22 Danziger Dan Flower Farm Otomeria plants
WO2013076730A1 (en) 2011-11-27 2013-05-30 Yeda Research And Development Co. Ltd. Methods of regulating angiogenesis and compositions capable of same
JP2015500279A (ja) 2011-12-08 2015-01-05 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 哺乳動物胎児肺細胞および該細胞の治療的使用
WO2013093921A1 (en) 2011-12-20 2013-06-27 Collplant Ltd. Collagen coated synthetic polymer fibers
EP2794107B1 (en) 2011-12-22 2021-08-11 Life Technologies Corporation Sequential lateral flow capillary device for analyte determination
EP2797421B1 (en) 2011-12-22 2020-05-20 Yeda Research And Development Co. Ltd. A combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion
EP2797405A1 (en) 2011-12-28 2014-11-05 Kaiima Bio Agritech Ltd. Cultivated sorghum plant having a partially or fully multiplied genome and uses of same
SG11201403756PA (en) 2012-01-01 2014-11-27 Qbi Entpr Ltd Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
WO2013114363A2 (en) 2012-01-30 2013-08-08 Yeda Research And Development Co.Ltd. Antimicrobial agents
US20150010527A1 (en) 2012-02-01 2015-01-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
WO2013118120A2 (en) 2012-02-06 2013-08-15 Rosetta Green Ltd. Isolated polynucleotides expressing or modulating micrornas or targets of same, transgenic plants comprising same and uses thereof in improving nitrogen use efficiency, abiotic stress tolerance, biomass, vigor or yield of a plant
CA2863795A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
DK3326642T3 (da) 2012-02-14 2021-02-22 Opko Biologics Ltd Langtidsvirkende koagulationsfaktorer og brugen deraf
BR112014021067A2 (pt) 2012-02-19 2018-10-30 Protalix Ltd formas unitárias de dosagem oral e usos das mesmas para o tratamento da doença de gaucher
US9803175B2 (en) 2012-02-22 2017-10-31 Exostem Biotec Ltd. Generation of neural stem cells and motor neurons
JP6329911B2 (ja) 2012-02-22 2018-05-23 ブレインステム バイオテック リミテッド 星状膠細胞作製のためのミクロrna
WO2013128454A1 (en) 2012-03-01 2013-09-06 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center Male sterile garlic plants, hybrid offspring of same and methods of generating and using same
US9631028B2 (en) 2012-03-07 2017-04-25 Yeda Research And Development Co. Ltd. Compositions for inhibition of quiescin sulfhydryl oxidase (QSOX1) and uses of same
EP2828280B1 (en) 2012-03-22 2018-05-02 Ramot at Tel-Aviv University Ltd. Plif multimeric peptides and uses thereof
CA2868238A1 (en) 2012-04-18 2013-10-24 Ramot At Tel Aviv University Ltd. Lipidated glycosaminoglycan particles for the delivery of nucleic acids
BR112014025951A2 (pt) 2012-04-19 2017-07-11 Opko Biologics Ltd variantes de oxintomodulina de longa ação e métodos de produção do mesmo
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
ES2627816T3 (es) 2012-05-09 2017-07-31 Yeda Research And Development Co. Ltd. Variantes del pro-dominio de tace como inhibidor de TNF-a y su uso médico
US8865158B2 (en) 2012-05-22 2014-10-21 Ramot At Tel-Aviv University Ltd. Bacteriophages for reducing toxicity of bacteria
MX360866B (es) 2012-05-24 2018-11-09 A B Seeds Ltd Composiciones y métodos para silenciar la expresión genética.
JP5868549B2 (ja) 2012-05-24 2016-02-24 マウントゲイト グループ リミテッド 狂犬病感染の予防および治療に関する組成物および方法
WO2013183048A1 (en) 2012-06-03 2013-12-12 Ben-Gurion University Of The Negev Research And Development Authority Functionalized titanium binding peptides and implants coated with same
CN109096387B (zh) 2012-06-04 2021-11-30 奥普科生物制品有限公司 聚乙二醇化的oxm变体
US10023474B2 (en) 2012-07-03 2018-07-17 Nanospun Technologies Ltd. Methods for adsorption and biodegradation of petroleum
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
DK2880155T3 (da) 2012-07-29 2019-07-15 Yeda Res & Dev Anvendelse af den reduktive glycinvej til generering af formatotrofiske og autotrofiske mikroorganismer
CN104684558A (zh) 2012-07-31 2015-06-03 耶达研究及发展有限公司 诊断和治疗运动神经元疾病的方法
JP6362596B2 (ja) 2012-08-06 2018-07-25 ブレインストーム セル セラペウティクス リミテッド 神経栄養因子を分泌する間葉系幹細胞の作製方法
US20140068814A1 (en) 2012-09-03 2014-03-06 A.B. Seeds Ltd. Method of improving abiotic stress tolerance of plants and plants generated thereby
US10543278B2 (en) 2012-09-12 2020-01-28 Ramot At Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
EP2906954B1 (en) 2012-10-09 2018-04-11 Ramot at Tel-Aviv University Ltd. Methods and kits for predicting prognosis of cancer using soluble mortalin in blood
US20150266970A1 (en) 2012-10-24 2015-09-24 Yeda Research And Development Co. Ltd. Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
WO2014068553A1 (en) 2012-10-29 2014-05-08 Yeda Research And Development Co. Ltd. Aptamers, multimeric aptamers and uses thereof
CN112661863A (zh) 2012-11-20 2021-04-16 奥普科生物制品有限公司 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法
MX2015004626A (es) 2012-11-29 2015-07-14 Yeda Res & Dev Metodos para prevenir metastasis de tumor, tratar y pronosticar cancer e identificar agentes que son inhibidores putativos de metastasis.
WO2015079413A2 (en) 2013-11-28 2015-06-04 Yeda Research And Development Co. Ltd. Synaptojanin-2 inhibitors and uses thereof
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
UY35251A (es) 2013-01-01 2014-07-31 Seeds Ltd Ab MOLÉCULAS DE dsRNA AISLADAS Y MÉTODOS PARA USARLAS PARA SILENCIAR MOLÉCULAS DIANA DE INTERÉS
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
WO2014108850A2 (en) 2013-01-09 2014-07-17 Yeda Research And Development Co. Ltd. High throughput transcriptome analysis
WO2014111936A1 (en) 2013-01-17 2014-07-24 Novellusdx Ltd. Methods and systems for identifying patient specific driver mutations
WO2014118785A1 (en) 2013-02-04 2014-08-07 Ramot At Tel-Aviv University Ltd. Generation of cytotoxic tumor specific cell lines and uses thereof
CA2902727C (en) 2013-03-06 2020-08-18 Protalix Ltd. Use of plant cells expressing a tnfalpha polypeptide inhibitor in therapy
US20160017021A1 (en) 2013-03-06 2016-01-21 Protalix Ltd. TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
WO2014164797A2 (en) 2013-03-13 2014-10-09 Monsanto Technology Llc Methods and compositions for weed control
UY35379A (es) 2013-03-13 2014-09-30 Monsanto Technology Llc ?métodos y composiciones para el control de malezas?.
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
ES2883580T3 (es) 2013-03-21 2021-12-09 Collplant Ltd Composiciones que comprenden colágeno y PRP para la regeneración de tejidos y su método de producción
CN105163749B (zh) 2013-03-24 2018-03-27 拜欧肯治疗有限公司 治疗骨髓性白血病的方法
BR112015026702A2 (pt) 2013-04-21 2018-02-06 Yeda Res And Developmente Co Ltd métodos de extermínio de células senescentes
ES2831424T3 (es) 2013-04-23 2021-06-08 Yeda Res & Dev Células madre pluripotentes naif aisladas y métodos para generarlas
CN105555796B (zh) 2013-04-25 2019-09-17 耶达研究及发展有限公司 抑制肽对治疗炎性疾病的用途
WO2014188423A1 (en) 2013-05-21 2014-11-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Treatment of mast cell related pathologies
WO2014191995A2 (en) 2013-05-27 2014-12-04 Rakuto Bio Technologies Ltd. Enzymatic system-containing cosmetic compositions
WO2014207744A1 (en) 2013-06-24 2014-12-31 Ramot At Tel-Aviv University Ltd. Omentum based scaffold and delivery system
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
MX359191B (es) 2013-07-19 2018-09-18 Monsanto Technology Llc Composiciones y métodos para controlar leptinotarsa.
WO2015015489A1 (en) 2013-07-30 2015-02-05 Biolinerx Ltd. Antibody for treating diabetes and autoimmune diseases
CN105849117B (zh) 2013-08-29 2017-12-12 耶达研究及发展有限公司 Na,K‑ATP酶的α2亚型的选择性抑制剂和用于降低眼内压的用途
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
IL228284A (en) 2013-09-03 2016-12-29 Technion Res & Dev Foundation Implants from cellular scaffolding and blood vessel stalk
WO2015033344A1 (en) 2013-09-05 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
WO2015037009A1 (en) 2013-09-16 2015-03-19 Plexicure Ltd. Isolated proteins capable of binding plexin-a4 and methods of producing and using same
WO2015040609A1 (en) 2013-09-17 2015-03-26 Yeda Research And Development Co. Ltd. Erk-derived peptides and uses thereof
US20160237404A1 (en) 2013-10-01 2016-08-18 Kadimastem Ltd. Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and the treatment of amyotrophic laterial sclerosis (als)
DK3060239T3 (da) 2013-10-21 2020-08-03 Opko Biologics Ltd Langtidsvirkende polypeptider og fremgangsmåder til fremstilling og indgivelse heraf
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2015059690A1 (en) 2013-10-24 2015-04-30 Yeda Research And Development Co. Ltd. Polynucleotides encoding brex system polypeptides and methods of using s ame
CA2928315C (en) 2013-10-31 2023-03-21 Biokine Therapeutics Ltd. Methods of treating acute myeloid leukemia with a flt3 mutation
UA120426C2 (uk) 2013-11-04 2019-12-10 Монсанто Текнолоджі Елелсі Композиція та спосіб для боротьби з членистоногими паразитами та зараженням шкідниками
EP3074391B1 (en) 2013-11-28 2019-07-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
ES2697757T3 (es) 2013-12-10 2019-01-28 Yeda Res & Dev Uso de enzimas que catalizan la síntesis de piruvato a partir de formiato y acetil-CoA y bacterias que expresan la misma
EP3116303B1 (en) 2014-01-15 2020-07-22 Monsanto Technology LLC Methods and compositions for weed control using epsps polynucleotides
WO2015114633A1 (en) 2014-01-30 2015-08-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
CN111068053A (zh) 2014-02-03 2020-04-28 耶路撒冷希伯来大学的益生研究开发有限公司 使用酪蛋白激酶i抑制剂以消耗干细胞的用途
CN106715695B (zh) 2014-02-05 2020-07-31 耶达研究及发展有限公司 用于治疗和诊断的微rna和包含所述微rna的组合物
EP3102607B1 (en) 2014-02-06 2018-08-22 Yeda Research and Development Co. Ltd. Anti cd84 antibodies, compositions comprising same and uses thereof
US20170101633A1 (en) 2014-02-10 2017-04-13 Protalix Ltd. Method of maintaining disease stability in a subject having gaucher's disease
JP6628253B2 (ja) 2014-02-11 2020-01-08 ブレインストーム セル セラペウティクス リミテッド 細胞の適性を判定する方法
EP3114483A1 (en) 2014-03-03 2017-01-11 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Method and device for detection of pseudomonas aeruginosa
EP2923709A1 (en) 2014-03-28 2015-09-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multi-component-multistage malaria vaccine
WO2015153339A2 (en) 2014-04-01 2015-10-08 Monsanto Technology Llc Compositions and methods for controlling insect pests
CA2945438C (en) 2014-04-10 2023-08-22 Bonus Therapeutics Ltd. Bone repair compositions
PT4026917T (pt) 2014-04-14 2024-02-12 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd Método e kit para determinar a morte de células ou de tecido ou a origem de tecidos ou de células de dna por análise de metilação do dna
EP3132057B1 (en) 2014-04-17 2019-10-16 Yeda Research and Development Co. Ltd. Methods and kits for analyzing dna binding moieties attached to dna
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
EP3766902A1 (en) 2014-04-27 2021-01-20 FameWave Ltd. Humanized antibodies against ceacam1
CN106460048B (zh) 2014-04-28 2021-01-05 耶达研究及发展有限公司 针对试剂的微生物组应答
WO2015170324A2 (en) 2014-05-04 2015-11-12 Forrest Innovations Ltd. Compositions for mosquito control and uses of same
EP3145947A2 (en) 2014-05-22 2017-03-29 Yeda Research and Development Co., Ltd. Recombinant microorganisms capable of carbon fixation
US20170095512A1 (en) 2014-06-02 2017-04-06 Kadimastem Ltd. Methods of inducing myelination and maturation of oligodendrocytes
US20170253881A1 (en) 2014-06-02 2017-09-07 Technion Research & Development Foundation Limited Compositions and methods of selectively inhibiting irp1 and treating inflammation
CA2953347A1 (en) 2014-06-23 2015-12-30 Monsanto Technology Llc Compositions and methods for regulating gene expression via rna interference
WO2015198320A1 (en) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
EP3161138A4 (en) 2014-06-25 2017-12-06 Monsanto Technology LLC Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
JP6587288B2 (ja) 2014-06-25 2019-10-09 テル ハショマー メディカル リサーチ インフラストラクチャー アンド サーヴィシーズ リミテッド がん幹細胞の同定ならびに診断および処置のためのその使用
WO2015198326A1 (en) 2014-06-26 2015-12-30 Ramot At Tel-Aviv University Ltd. Liposomal formulations for delivery of nucleic acids
WO2016005985A2 (en) 2014-07-09 2016-01-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method for reprogramming cells
HUE049261T2 (hu) 2014-07-15 2020-09-28 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd CD44 izolált polipeptidek és alkalmazásaik
CA2955414A1 (en) 2014-07-21 2016-01-28 Novellusdx Ltd. Methods and systems for determining oncogenic index of patient specific mutations
JP6700249B2 (ja) 2014-07-21 2020-06-10 ノベルラスディクス リミテッド 患者特有の変異の薬物応答を測定する方法
CN114009454A (zh) 2014-07-29 2022-02-08 孟山都技术公司 用于控制昆虫害虫的组合物和方法
US11920164B2 (en) 2014-07-30 2024-03-05 Yeda Research And Development Co. Ltd. Media for culturing naive human pluripotent stem cells
EP3699930B1 (en) 2014-08-14 2024-02-07 MeMed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
WO2016030899A1 (en) 2014-08-28 2016-03-03 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral scleroses
AU2015313811A1 (en) 2014-09-08 2017-04-06 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
WO2016038609A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
EP2992895A1 (en) 2014-09-08 2016-03-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Three-component-multistage malaria vaccine
IL234638A0 (en) 2014-09-14 2014-12-02 Yeda Res & Dev NMDA receptor antagonists for the treatment of Gaucher disease
CN106999608A (zh) 2014-09-21 2017-08-01 耶路撒冷希伯来大学伊森姆研究发展公司 为了治疗脂质相关病症而下调mir‑132
EP3209799B1 (en) 2014-10-20 2020-07-08 Gen-Probe Incorporated Red blood cell lysis solution
ES2965744T3 (es) 2014-11-13 2024-04-16 Enzootic Holdings Ltd Inversión sexual funcional de crustáceos decápodos hembras
CA2967233A1 (en) 2014-11-17 2016-05-26 Yeda Research And Development Co. Ltd. Method of analyzing microbiome
US20180042994A1 (en) 2014-11-17 2018-02-15 Yeda Research And Development Co. Ltd. Methods of treating diseases related to mitochondrial function
WO2016079739A2 (en) 2014-11-20 2016-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells
JP6860483B2 (ja) 2014-11-26 2021-04-14 テクノロジー イノベーション モメンタム ファンド(イスラエル)リミテッド パートナーシップTechnology Innovation Momentum Fund(israel)Limited Partnership 細菌遺伝子の標的化削減
KR20170081268A (ko) 2014-11-27 2017-07-11 단지거 이노베이션즈 엘티디. 게놈 편집용 핵산 구조체
WO2016092555A2 (en) 2014-12-11 2016-06-16 Yeda Research And Development Co. Ltd. Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2016103269A1 (en) 2014-12-23 2016-06-30 Ramot At Tel-Aviv University Ltd. Populations of neural progenitor cells and methods of producing and using same
EP3916085A1 (en) 2014-12-30 2021-12-01 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
IL305070A (en) 2014-12-30 2023-10-01 Cell Cure Neurosciences Ltd RPE cell populations and methods for their production
WO2016108219A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Methods of treating retinal diseases
EP3240896A1 (en) 2015-01-04 2017-11-08 Protalix Ltd. Modified dnase and uses thereof
WO2016116935A1 (en) 2015-01-21 2016-07-28 Yeda Research And Development Co. Ltd. Use of rasa2 as a prognostic and therapeutic marker for melanoma
PL3256589T3 (pl) 2015-01-22 2022-02-21 Monsanto Technology Llc Kompozycje i sposoby kontrolowania leptinotarsa
WO2016135732A1 (en) 2015-02-26 2016-09-01 Yeda Research And Development Co. Ltd. Method of promoting hair growth
EP3268475B1 (en) 2015-03-11 2020-10-21 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Decoy oligonucleotides for the treatment of diseases
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
ES2904573T3 (es) 2015-03-27 2022-04-05 Univ Southern California Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos
EP4218771A1 (en) 2015-03-27 2023-08-02 Yeda Research and Development Co. Ltd Methods of treating motor neuron diseases
RU2017135552A (ru) 2015-03-31 2019-04-30 Иеда Рисеч Энд Девелопмент Ко. Лтд. Глутамат оксалоацетат трансаминаза 1 (got1), препараты и способы их получения и применения
EP3277260B1 (en) 2015-04-01 2021-05-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Erodium crassifolium l'her plant extracts and uses thereof
CA2981732C (en) 2015-04-07 2024-03-12 Boris Khalfin Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
EP3081575A1 (en) 2015-04-12 2016-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-plasmodium parasite antibodies
CA2986202C (en) 2015-04-27 2023-08-22 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Egr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
AU2016255724B2 (en) 2015-04-29 2020-05-14 The State of Israel, Ministry of Agriculture and Rural Development Agricultural Research Organization (ARO) (Volcani Center) Anti-phytopathogenic compositions
US20190031759A1 (en) 2015-04-30 2019-01-31 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
US11845928B2 (en) 2015-05-04 2023-12-19 Tsinghua University Methods and kits for fragmenting DNA
EP3294280A1 (en) 2015-05-11 2018-03-21 Yeda Research and Development Co., Ltd. Citrin inhibitors for the treatment of cancer
WO2016185471A1 (en) 2015-05-17 2016-11-24 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Compositions and methods for treating cancer
WO2016185457A1 (en) 2015-05-19 2016-11-24 Yeda Research And Development Co. Ltd. Methods of promoting lymphangiogenesis
WO2016185481A2 (en) 2015-05-20 2016-11-24 Yeda Research And Development Co. Ltd. Method of targeting senescent cells
JP2018515564A (ja) 2015-05-21 2018-06-14 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. 健康増進のための細菌群
MX2017015375A (es) 2015-05-29 2018-06-19 Opko Biologics Ltd Variantes de oxintomodulina pegilada.
AU2016270870A1 (en) 2015-06-02 2018-01-04 Monsanto Technology Llc Compositions and methods for delivery of a polynucleotide into a plant
AU2016270913A1 (en) 2015-06-03 2018-01-04 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
JP7010473B2 (ja) 2015-06-04 2022-02-10 ユニバーシティ オブ サザン カリフォルニア Lym-1およびlym-2標的化car細胞免疫療法
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
WO2016203476A1 (en) 2015-06-18 2016-12-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and compositions for diagnosing and treating urothelial cancer
EP4026563A1 (en) 2015-06-18 2022-07-13 Yeda Research and Development Co. Ltd Conditioning protocols and use of same for tissue regeneration
EP3310347B1 (en) 2015-06-19 2021-08-04 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10933124B2 (en) 2015-07-16 2021-03-02 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
KR20180063881A (ko) 2015-07-16 2018-06-12 바이오카인 테라퓨틱스 리미티드 암 치료용 조성물 및 방법
EP3325494B1 (en) 2015-07-19 2020-12-30 Yeda Research and Development Co., Ltd. Selective inhibitors of alpha2-containing isoforms of na,k-atpase and use thereof for reducing intraocular pressure
BR112018001310A2 (pt) 2015-07-22 2018-09-11 Phytopharma Int Ltd composições ingeríveis por abelha, métodos de uso das mesmas para a produção de mel e mel produzido por estas
US11230696B2 (en) 2015-07-29 2022-01-25 Hadasit Medical Research Services And Development Ltd. Large scale production of retinal pigment epithelial cells
US20180221393A1 (en) 2015-08-03 2018-08-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases
EP3332009A1 (en) 2015-08-04 2018-06-13 Yeda Research and Development Co., Ltd. Methods of screening for riboswitches and attenuators
JP6868608B2 (ja) 2015-08-05 2021-05-12 セル キュア ニューロサイエンシズ リミテッド 網膜疾患の処置のための光受容体の調製
EP3331994B1 (en) 2015-08-05 2022-09-14 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
US10639350B2 (en) 2015-08-10 2020-05-05 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods and pharmaceutical compositions for improving wound healing using CD24
US20180237790A1 (en) 2015-08-13 2018-08-23 Forrest Innovation Ltd. Formulations and compositions for delivery of nucleic acids to plant cells
WO2017033188A1 (en) 2015-08-24 2017-03-02 Yeda Research And Development Co. Ltd. Algal oil and biofuel and methods of producing same
US10765706B2 (en) 2015-09-03 2020-09-08 University Of South Florida Method of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers
WO2017042816A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Ablation of perforin positive dendritic cells in cancer treatment
WO2017072757A1 (en) 2015-10-25 2017-05-04 Yeda Research And Development Co. Ltd. Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same
AU2016347652A1 (en) 2015-10-26 2018-05-24 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
CA3187317A1 (en) 2015-10-27 2017-05-04 Jay Pharma, Inc. Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
IL242380A0 (en) 2015-10-29 2016-02-01 Yeda Res & Dev A method for inducing the division of cardiomyocytes and treating heart diseases
WO2017077539A1 (en) 2015-11-03 2017-05-11 Ariel-University Research And Development Company Ltd. Compositions for regeneration and repair of neural tissue
US20180327855A1 (en) 2015-11-11 2018-11-15 Ramot At Tel-Aviv University Ltd. Methods of detecting 5-hydroxymethylcytosine and diagnosing of cancer
WO2017094001A1 (en) 2015-11-30 2017-06-08 Kadimastem Ltd Methods for differentiating and purifying pancreatic endocrine cells
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
EP4059507B1 (en) 2015-12-16 2024-06-05 Ramot at Tel-Aviv University Ltd. Particles comprising decellularized omentum
WO2017115367A1 (en) 2015-12-28 2017-07-06 The National Institute for Biotechnology in the Negev Ltd. Composition and method for treating amyotrophic lateral sclerosis
AU2017204950A1 (en) 2016-01-06 2018-08-16 Yeda Research And Development Co. Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases
WO2017122203A1 (en) 2016-01-11 2017-07-20 Technion Research & Development Foundation Limited Methods of determining prognosis of sepsis and treating same
EP3405024B1 (en) 2016-01-21 2022-12-28 The State of Israel - Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Parthenocarpic plants and methods of producing same
IL243839B (en) 2016-01-28 2018-01-31 Sp Nano Ltd Conductive wires
IL243838A (en) 2016-01-28 2017-07-31 Sp Nano Ltd The composition containing sp1 protein and carbon nanoparticles and its uses
WO2017130205A1 (en) 2016-01-31 2017-08-03 Hadasit Medical Research Services And Development Ltd. Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof
US11230578B2 (en) 2016-02-04 2022-01-25 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant P53
US20190046497A1 (en) 2016-02-14 2019-02-14 Yeda Research And Development Co., Ltd. Methods of modulating protein exocytosis and uses of same in therapy
EP3414346B1 (en) 2016-02-14 2019-11-13 Yeda Research and Development Co. Ltd. Microbiome-based diagnosis, prediction and treatment of relapsing obesity
MX2018009984A (es) 2016-02-16 2019-01-21 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Análogos no proteínicos de fenilananina para la inhibicion del crecimiento de cianobacterias y plantas.
WO2017145162A1 (en) 2016-02-23 2017-08-31 Chaya Brodie Generation of cancer stem cells and use thereof
SG11201807437XA (en) 2016-03-01 2018-09-27 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Antibodies specific to human poliovirus receptor (pvr)
CN108699609A (zh) 2016-03-03 2018-10-23 米密德诊断学有限公司 分析rna用于诊断感染类型
US20190216891A1 (en) 2016-03-06 2019-07-18 Yeda Research And Development Co., Ltd. Method for modulating myelination
IL244649A0 (en) 2016-03-17 2016-06-30 Yeda Res & Dev Methods for the isolation of barrel-like proteases and the identification of peptides that are cleaved by Alidan
US10421785B2 (en) 2016-04-11 2019-09-24 Bar-Ilan University Delta receptor agonist peptides and use thereof
EP3448998B1 (en) 2016-04-27 2020-06-03 Gen-Probe Incorporated Blood cell lysis reagent
CN109475581A (zh) 2016-05-22 2019-03-15 耶达研究及发展有限公司 为了移植及诱导耐受性而使用肺细胞的方法
IL245861A0 (en) 2016-05-25 2016-09-04 Yeda Res & Dev Use of substances to treat drug-resistant tumors
WO2017208247A1 (en) 2016-06-02 2017-12-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Assay for the removal of methyl-cytosine residues from dna
EP3464322B1 (en) 2016-06-05 2023-04-05 Tel HaShomer Medical Research Infrastructure and Services Ltd. Novel molecules for the treatment of inflammation
EP3468610A1 (en) 2016-06-09 2019-04-17 OPKO Biologics Ltd. Long-acting oxyntomodulin formulation and methods of producing and administering same
WO2017221225A1 (en) 2016-06-19 2017-12-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Screening for chemotherapy resistance in human haploid cells
JP7334043B2 (ja) 2016-06-27 2023-08-28 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド メモリーt細胞から作られるベト細胞
EP3482200B1 (en) 2016-07-10 2022-05-04 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
EP3482201B1 (en) 2016-07-10 2022-12-14 Memed Diagnostics Ltd. Early diagnosis of infections
KR20240006077A (ko) 2016-07-11 2024-01-12 옵코 바이오로직스 리미티드 지속성 응고 인자 vii 및 그 제조 방법
IL246722A0 (en) 2016-07-11 2016-09-29 Yeda Res & Dev Combined treatment to increase endogenous synthesis of nitric oxide
US20190224244A1 (en) 2016-07-11 2019-07-25 Bonus Therapeutics Ltd. Cell compositions for tissue regeneration
EP3481191A2 (en) 2016-07-11 2019-05-15 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Systems and methods for growing cells in vitro
EP4434516A2 (en) 2016-07-18 2024-09-25 Ramot at Tel-Aviv University Ltd. Modular platform for targeted therapeutics
WO2018020489A1 (en) 2016-07-24 2018-02-01 Yeda Research And Development Co. Ltd. Methods and kits for analyzing dna binding moieties attached to dna
EP3497231B1 (en) 2016-08-08 2023-10-04 Technology Innovation Momentum Fund (Israel) Limited Partnership Bacterial systems for analyzing ubiquitylated polypeptides
EP3497239A4 (en) 2016-08-10 2020-02-26 Ramot at Tel-Aviv University Ltd. METHYLATION STATUS ANALYSIS AND COPY NUMBER
CN109844532B (zh) 2016-08-10 2022-06-17 米密德诊断学有限公司 分析生物数据的系统和方法
PL3496730T3 (pl) 2016-08-14 2022-09-26 Ramot At Tel-Aviv University Ltd. Egzosomy pochodzące z komórek mezenchymalnych do leczenia zaburzeń neurologicznych
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
WO2018037416A1 (en) 2016-08-25 2018-03-01 Yeda Research And Development Co. Ltd. Methods and compositions for treating autoimmune diseases
WO2018047154A1 (en) 2016-09-07 2018-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-nkp46 antibodies and therapeutic use of same
EP3512943B1 (en) 2016-09-14 2023-04-12 Yeda Research and Development Co. Ltd. Crisp-seq, an integrated method for massively parallel single cell rna-seq and crispr pooled screens
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
IL248468A0 (en) 2016-10-13 2017-01-31 Technion Res & Dev Foundation Use of caspase-3 inhibitors and caspase-3 activators in the preparation of medical preparations for cancer treatment and wound healing
IL248385A0 (en) 2016-10-18 2017-02-01 Yeda Res & Dev Treatment of circadian rhythm disorder
EP3538651A1 (en) 2016-11-10 2019-09-18 Yeda Research and Development Co., Ltd. Phosphotriesterases for treating or preventing organophosphate exposure associated damage
CN110234765A (zh) 2016-11-28 2019-09-13 耶达研究及发展有限公司 分离的多核苷酸和多肽及使用它们来表达感兴趣的表达产物的方法
EP3548015A1 (en) 2016-11-30 2019-10-09 Yeda Research and Development Co. Ltd. Methods of treating liver toxicity and disorders
EP3548106B1 (en) 2016-12-01 2023-01-04 Ramot at Tel-Aviv University Ltd. Combined treatment for nerve injuries
EP3571295A1 (en) 2017-01-18 2019-11-27 Yeda Research and Development Co. Ltd Genetically modified veto cells and use of same in immunotherapy
IL250479A0 (en) 2017-02-06 2017-03-30 Sorek Rotem Genetically engineered cells expressing a disarm system that confers resistance to phages and methods for their production
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
WO2018167780A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
US20200150125A1 (en) 2017-03-12 2020-05-14 Yeda Research And Development Co., Ltd. Methods of diagnosing and prognosing cancer
CN118021843A (zh) 2017-03-16 2024-05-14 谱系细胞疗法公司 用于测量视网膜疾病疗法的疗效的方法
CN110678543B (zh) 2017-04-05 2024-04-09 耶达研究及发展有限公司 体外培养系统及其使用方法
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Treatment of stress disorders
KR20200004880A (ko) 2017-05-10 2020-01-14 아리엘 싸이언티픽 이노베이션스 엘티디. 항체를 정제하는 방법
WO2018216006A1 (en) 2017-05-21 2018-11-29 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Combination of markers for diagnosing cancer
EP3634991A1 (en) 2017-05-23 2020-04-15 Technion Research & Development Foundation Limited Agents which inhibit gads dimerization and methods of use thereof
GB201708665D0 (en) 2017-05-31 2017-07-12 Tropic Biosciences Uk Ltd Compositions and methods for increasing extractability of solids from coffee beans
GB201708662D0 (en) 2017-05-31 2017-07-12 Tropic Biosciences Uk Ltd Compositions and methods for increasing shelf-life of banana
WO2018220582A1 (en) 2017-05-31 2018-12-06 Tropic Biosciences UK Limited Methods of selecting cells comprising genome editing events
WO2018229764A1 (en) 2017-06-13 2018-12-20 Yeda Research And Development Co. Ltd. Treatment of advanced or progressive multiple sclerosis
US11466323B2 (en) 2017-07-13 2022-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Dual-probe digital droplet PCR strategy for specific detection of tissue-specific circulating DNA molecules
EP3652342A1 (en) 2017-07-13 2020-05-20 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Detecting tissue-specific dna
EP4403646A2 (en) 2017-07-13 2024-07-24 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Dna targets as tissue-specific methylation markers
IL253642A0 (en) 2017-07-24 2017-09-28 Seger Rony Combined treatment for cancer
IL253984A0 (en) 2017-08-14 2017-09-28 Yeda Res & Dev Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1
WO2019038771A1 (en) 2017-08-23 2019-02-28 Technion Research & Development Foundation Limited COMPOSITIONS AND METHODS FOR ENHANCING ALCOHOL TOLERANCE IN YEAST
AU2018336128B2 (en) 2017-09-19 2023-01-05 Tropic Biosciences UK Limited Modifying the specificity of plant non-coding RNA molecules for silencing gene expression
WO2019094595A2 (en) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
IL255664A0 (en) 2017-11-14 2017-12-31 Shachar Idit Hematopoietic stem cells with enhanced properties
WO2019106671A1 (en) 2017-11-29 2019-06-06 Ramot At Tel-Aviv University Ltd. Methods of preventing or treating neurogenic shock
WO2019106667A1 (en) 2017-11-29 2019-06-06 Weedout Ltd. Compositions, kits and methods for controlling weed of the amaranthus genus
EP3716993A1 (en) 2017-12-03 2020-10-07 Yeda Research and Development Co. Ltd Treatment of an ischemic heart disease
WO2019116376A1 (en) 2017-12-17 2019-06-20 Yeda Research And Development Co. Ltd. Cop9 signalosome (csn) complex modulators and uses thereof
EP3731965A1 (en) 2017-12-28 2020-11-04 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Method to reproduce circadian rhythms on a microfluidic chip
IL257225A (en) 2018-01-29 2018-04-09 Yeda Res & Dev Treatment of sarcoma
IL257269A (en) 2018-01-31 2018-04-09 Olender Tsviya Signaling is directed to the endoplasmic reticulum
EP3749368A1 (en) 2018-02-08 2020-12-16 Yeda Research and Development Co. Ltd Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
WO2019155459A1 (en) 2018-02-08 2019-08-15 Yeda Research And Development Co. Ltd. Inhibitors of the 20s proteasome
WO2019162945A1 (en) 2018-02-23 2019-08-29 Carmel Haifa University Economic Corporation Ltd. Methods for treating memory impairment and cognitive dysfunction
US20200408761A1 (en) 2018-02-28 2020-12-31 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods of diagnosing and treating bladder cancer
WO2019175869A1 (en) 2018-03-12 2019-09-19 Yeda Research And Development Co. Ltd Treatment of a heart disease
CN112236131A (zh) 2018-03-29 2021-01-15 技术研究及发展基金有限公司 包含pten抑制剂的囊泡及其用途
IL258467A (en) 2018-03-29 2018-07-04 Ilana Kolodkin Gal Methods of disrupting a biofilm and/or preventing formation of same
EP3774047A1 (en) 2018-03-29 2021-02-17 Yeda Research and Development Co. Ltd Use of electric field gradients to control gene expression
GB201807192D0 (en) 2018-05-01 2018-06-13 Tropic Biosciences Uk Ltd Compositions and methods for reducing caffeine content in coffee beans
IL259392A (en) 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neo-antigens
WO2019220441A1 (en) 2018-05-15 2019-11-21 Hadasit Medical Research Services And Development Ltd. Compositions and methods for treating cancer resistant to an anti-cancer agent
US20210121491A1 (en) 2018-05-27 2021-04-29 Biolinerx Ltd. Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors
US11827892B2 (en) 2018-06-07 2023-11-28 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Nucleic acid constructs and methods of using same
CN112384063A (zh) 2018-06-07 2021-02-19 以色列国家农业部、农村发展农业研究组织·沃尔卡尼中心 再生及转殖大麻的方法
EP3810636A1 (en) 2018-06-25 2021-04-28 Yeda Research and Development Co. Ltd Systems and methods for increasing efficiency of genome editing
WO2020008412A1 (en) 2018-07-04 2020-01-09 Ukko Inc. Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease
US20210269860A1 (en) 2018-07-08 2021-09-02 Yeda Research And Development Co. Ltd. Person-specific assessment of probiotics responsiveness
WO2020012486A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
JP7395517B2 (ja) 2018-07-11 2023-12-11 イミュニティ ファルマ リミテッド ペプチド化合物およびその治療的用途
AU2019315054A1 (en) 2018-07-31 2021-03-18 Collplant Ltd. Tobacco transgenic event and methods for detection and use thereof
IL261156A (en) 2018-08-14 2020-02-27 Fass Deborah Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same
CA3108434A1 (en) 2018-08-24 2020-02-27 Yeda Research And Development Co. Ltd. Methods of modulating m2 macrophage polarization and use of same in therapy
CN113038951B (zh) 2018-09-20 2024-04-30 耶达研究及发展有限公司 治疗肌萎缩侧索硬化的方法
WO2020065647A1 (en) 2018-09-25 2020-04-02 Biolinerx Ltd. Methods of selecting treatment for cxcr4-associated cancer
IL262658A (en) 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
IL263184A (en) 2018-11-21 2020-05-31 Yarden Yosef Method of treating cancer and compositions for same
EP3914698A1 (en) 2019-01-23 2021-12-01 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
IL264768A (en) 2019-02-10 2020-08-31 Sagi Irit ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) inhibitory antibody and its use
IL264854A (en) 2019-02-14 2020-08-31 Bahat Anat Spt5 inhibitors and methods of use thereof
EP3927807A1 (en) 2019-02-21 2021-12-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Methods of generating organoids for high throughput screening of drugs
JP2022521010A (ja) 2019-02-21 2022-04-04 イッスム・リサーチ・デベロプメント・カムパニー・オブ・ザ・ヘブリュー・ユニバシティー・オブ・エルサレム リミテッド 薬物誘導性腎毒性を減少させるための方法
MX2021010611A (es) 2019-03-05 2021-11-12 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Aves con genoma editado.
EP3938400A4 (en) 2019-03-11 2022-11-23 Memorial Sloan Kettering Cancer Center CD22 ANTIBODIES AND METHODS OF USE THEREOF
GB201903520D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells
GB201903519D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest
GB201903521D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd No title
IL265486A (en) 2019-03-19 2020-09-30 Yeda Res & Dev Bistable type ii opsins and uses thereof
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
WO2020202142A2 (en) 2019-03-31 2020-10-08 Yeda Research And Development Co. Ltd. Anti-viral and anti-tumoral compounds
IL266433B (en) 2019-05-02 2020-11-30 Sagi Irit Compositions comprising the propeptide of lysyl oxidase and uses thereof
US20220220559A1 (en) 2019-05-13 2022-07-14 Yeda Research And Development Co. Ltd. Cell-free mirna biomarkers for prognosis and diagnosis of neurodegenerative diseases
IL266728B (en) 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutant neopeptides
US20220213445A1 (en) 2019-05-22 2022-07-07 Hadasit Medical Research Services And Development Ltd. Methods of culturing human pluripotent cells
CA3140406A1 (en) 2019-05-28 2020-12-03 Shanghaitech University Composition and methods to treat ectodermal dysplasia 2, clouston type
JP2022536326A (ja) 2019-06-12 2022-08-15 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド オリゴデンドロサイトの産生方法
WO2020255124A1 (en) 2019-06-16 2020-12-24 Yeda Research And Development Co. Ltd. Method for stabilizing intracellular rna
WO2020261281A1 (en) 2019-06-27 2020-12-30 Ramot At Tel-Aviv University Ltd. Semaphorin 3a antibodies and uses thereof
EP3994268A1 (en) 2019-07-04 2022-05-11 Ukko Inc. De-epitoped alpha gliadin and use of same for the management of celiac disease and gluten sensitivity
JP2022541742A (ja) 2019-07-11 2022-09-27 カール メディカル リミテッド ヘテロダイマーおよびその使用方法
US20220281960A1 (en) 2019-07-16 2022-09-08 Ramot At Tel-Aviv University Ltd. Compositions and methods for the treatment of tuberculosis
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
CA3147575A1 (en) 2019-07-29 2021-02-04 Yeda Research And Development Co. Ltd. Methods of treating and diagnosing lung cancer
EP4004212A1 (en) 2019-07-30 2022-06-01 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Institute) Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby
EP4014046A1 (en) 2019-08-12 2022-06-22 Yeda Research and Development Co. Ltd Dna repair blood test for predicting response of lung cancer patients to immunotherapy
US20240140988A1 (en) 2019-08-22 2024-05-02 Ariel Scientific Innovations Ltd. Scaled-up methods for purifying antibodies
EP4021463A1 (en) 2019-08-27 2022-07-06 Yeda Research and Development Co. Ltd Treatment of bacterial vaginosis
WO2021048852A1 (en) 2019-09-11 2021-03-18 Yeda Research And Development Co. Ltd. Methods of treating breast cancer
IL269674B (en) 2019-09-25 2020-08-31 Roy Bar Ziv Assembling protein complexes on a chip
IL270306A (en) 2019-10-30 2021-05-31 Yeda Res & Dev Prevention and treatment of pre-myeloid and myeloid malignancies
WO2021084526A1 (en) 2019-10-31 2021-05-06 Yeda Research And Development Co. Ltd. Engineered autotrophic bacteria for co2 conversion to organic materials
MX2022005678A (es) 2019-11-11 2022-10-18 Ibi Ag Innovative Bio Insecticides Ltd Nanocuerpos para el control de insectos y usos de los mismos.
WO2021100034A1 (en) 2019-11-19 2021-05-27 Protalix Ltd. Removal of constructs from transformed cells
IL270800A (en) 2019-11-20 2021-05-31 Yeda Res & Dev A method for treating Alzheimer's disease
EP4077731A1 (en) 2019-12-22 2022-10-26 Yeda Research and Development Co. Ltd Diagnosis of frontotemporal dementia
IL271656A (en) 2019-12-22 2021-06-30 Yeda Res & Dev System and methods for identifying cells that have undergone genome editing
IL271778A (en) 2019-12-31 2021-06-30 Ichilov Tech Ltd Methods for treating atopic dermatitis
WO2021137230A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells and uses of same
WO2021137231A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
IL272074B1 (en) 2020-01-15 2024-08-01 Immunity Pharma Ltd Peptide compounds and their use in methods of treating diseases
IL272194A (en) 2020-01-22 2021-07-29 Yeda Res & Dev Multi-target antibodies for use in the treatment of diseases
WO2021152584A1 (en) 2020-01-28 2021-08-05 Ariel Scientific Innovations Ltd. Methods of analyzing cell membranes
IL272389A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
EP4096647A1 (en) 2020-01-30 2022-12-07 Yeda Research and Development Co. Ltd Treating acute liver disease with tlr-mik inhibitors
IL272390A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Cancer treatment methods
WO2021152586A1 (en) 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Methods of analyzing microbiome, immunoglobulin profile and physiological state
KR20220151168A (ko) 2020-02-09 2022-11-14 엔엘씨 파르마 엘티디 Sars-cov-2에 대한 신속한 검출 테스트
IL272586A (en) 2020-02-10 2021-08-31 Yeda Res & Dev A method for cell cluster analysis
WO2021173674A1 (en) 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
US20230127559A1 (en) 2020-03-16 2023-04-27 Yeda Research And Development Co. Ltd. Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein
AU2021245409A1 (en) 2020-03-29 2022-11-24 Yeda Research And Development Co. Ltd. Variants of beta-glucocerebrosidase for use in treating Gaucher Disease
IL296698A (en) 2020-03-31 2022-11-01 Biomuse Ltd Bacteria for the prevention and treatment of smoking damage to the lungs
EP4133107A1 (en) 2020-04-06 2023-02-15 Yeda Research and Development Co. Ltd Methods of diagnosing cancer and predicting responsiveness to therapy
EP4132479A1 (en) 2020-04-07 2023-02-15 Ramot at Tel-Aviv University Ltd. Cannabidiol-containing compositions and uses thereof
IL297228A (en) 2020-04-13 2022-12-01 Exoprother Medical Ltd Cellular vesicles containing non-mutant p53 for antiviral therapy
US20210322483A1 (en) 2020-04-16 2021-10-21 Ichilov Tech Ltd. Cell-derived particles presenting heterologous cd24 and use thereof in therapy
WO2021229577A1 (en) 2020-05-12 2021-11-18 Collplant Ltd. Collagen as a delivery tool for metal-based anti-viral agents
IL274811B (en) 2020-05-20 2021-05-31 Yeda Res & Dev Spatial information is developed for the analysis of individual cells
IL299276A (en) 2020-06-22 2023-02-01 Univ Ramot Protein modules with cell subunits that express them and their uses
US20230293530A1 (en) 2020-06-24 2023-09-21 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
IL276627A (en) 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
EP4199703A1 (en) 2020-08-18 2023-06-28 International Rice Research Institute Methods of increasing outcrossing rates in gramineae
IL277488A (en) 2020-09-21 2022-04-01 Yeda Res & Dev Weight regulation method
IL301503A (en) 2020-09-23 2023-05-01 Yeda res & development co ltd Methods and preparations for the treatment of the disease caused by the corona virus
IL277743A (en) 2020-10-01 2022-04-01 Yeda Res & Dev A method for diagnosing breast cancer
JP2023545999A (ja) 2020-10-05 2023-11-01 プロタリクス リミテッド ダイサー(dicer)様ノックアウト植物細胞
WO2022074656A1 (en) 2020-10-07 2022-04-14 Protalix Ltd. Long-acting dnase
WO2022079719A1 (en) 2020-10-15 2022-04-21 Yeda Research And Development Co. Ltd. Method of treating myeloid malignancies
IL278401A (en) 2020-10-29 2022-05-01 Yeda Res & Dev Polynucleotides for editing RNA and a method for using them
WO2022097157A2 (en) 2020-11-09 2022-05-12 1E Therapeutics, Ltd. Catalytic sequence based methods of treating or preventing bacterial infections
JP2023550979A (ja) 2020-11-26 2023-12-06 ウッコ インコーポレイテッド 改変された高分子量グルテニンサブユニット及びその使用
IL279559A (en) 2020-12-17 2022-07-01 Yeda Res & Dev Controlling the ubiquitination process of mlkl for disease treatment
IL304068A (en) 2020-12-28 2023-08-01 1E Therapeutics Ltd DNA enzymes against p21 messenger RNA
IL304047A (en) 2020-12-28 2023-08-01 1E Therapeutics Ltd Silencing target sites in the p21 mRNA sequence
EP4274886A2 (en) 2021-01-10 2023-11-15 Supermeat the Essence of Meat Ltd. Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry
US20240083843A1 (en) 2021-01-14 2024-03-14 Yeda Research And Development Co. Ltd. Methods of producing vitamin d
IL280340B (en) 2021-01-21 2022-04-01 Yeda Res & Dev Antibodies, peptides and their combinations for the treatment and prevention of corona virus infections
JP2024506955A (ja) 2021-02-18 2024-02-15 イェダ リサーチ アンド デベロップメント カンパニー リミテッド ワクチンを作製する方法
JP2024506954A (ja) 2021-02-18 2024-02-15 イェダ リサーチ アンド デベロップメント カンパニー リミテッド ワクチン作製用の遺伝子改変細菌
IL281561A (en) 2021-03-16 2022-10-01 Yeda Res & Dev Methods and devices for growing mouse embryos outside the uterus
CA3213424A1 (en) 2021-03-30 2022-10-06 Lior Moshe ZELCBUCH Pseudomonas bacteriophage and uses thereof
IL282188A (en) 2021-04-08 2022-11-01 Yeda Res & Dev Combined use of ketamine and bretigabine for the treatment of psychiatric disorders
EP4337764A1 (en) 2021-05-12 2024-03-20 Biomx Ltd. Staphylococcus bacteriophage and uses thereof
IL283563A (en) 2021-05-30 2022-12-01 Yeda Res & Dev Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases
CA3219233A1 (en) 2021-06-06 2022-12-15 Ravid STRAUSSMAN Combined treatment for cancer
JP2024534404A (ja) 2021-06-13 2024-09-20 イッスム・リサーチ・デベロプメント・カムパニー・オブ・ザ・ヘブリュー・ユニバシティー・オブ・エルサレム リミテッド ヒト細胞を再プログラミングする方法
MX2023015233A (es) 2021-06-16 2024-01-31 Seedx Tech Inc Metodos de clasificacion de semillas de matthiola.
NL2028466B1 (en) 2021-06-16 2022-12-21 Sakata Holland B V Methods of sorting matthiola seeds
WO2023275255A1 (en) 2021-07-02 2023-01-05 Tropic Biosciences UK Limited Delay or prevention of browning in banana fruit
CN117980470A (zh) 2021-07-18 2024-05-03 盖米达细胞有限公司 治疗性nk细胞群
WO2023002492A1 (en) 2021-07-22 2023-01-26 Yeda Research And Development Co. Ltd. Codon optimization of nucleic acids
WO2023012584A2 (en) 2021-08-03 2023-02-09 Genicity Limited Engineered tcr complex and methods of using same
EP4130028A1 (en) 2021-08-03 2023-02-08 Rhazes Therapeutics Ltd Engineered tcr complex and methods of using same
WO2023018621A1 (en) 2021-08-10 2023-02-16 Gamida-Cell Ltd. Engineered nk cells, methods of their production and uses thereof
GB202112865D0 (en) 2021-09-09 2021-10-27 Tropic Biosciences Uk Ltd Resistance to black sigatoka disease in banana
GB202112866D0 (en) 2021-09-09 2021-10-27 Tropic Biosciences Uk Ltd Resistance to fusarium wilt in a banana
IL286430A (en) 2021-09-14 2023-04-01 Yeda Res & Dev Multispecific antibodies for use in the treatment of diseases
CN118696122A (zh) 2021-12-08 2024-09-24 耶达研究及发展有限公司 用于肺再生的多能肺祖细胞
WO2023209708A1 (en) 2022-04-25 2023-11-02 Yeda Research And Development Co. Ltd. Compositions for altering cyclic adp-ribose secondary messenger signalling

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US3652761A (en) * 1969-09-04 1972-03-28 Corning Glass Works Immunochemical composites and antigen or antibody purification therewith

Also Published As

Publication number Publication date
ES398372A1 (es) 1975-06-16
DK150690C (da) 1988-06-06
IL38371A (en) 1974-06-30
GB1348938A (en) 1974-03-27
AT320145B (de) 1975-01-27
ZA718332B (en) 1972-09-27
DE2164768A1 (de) 1972-07-20
FI54034C (fi) 1978-09-11
FI54034B (fi) 1978-05-31
US3839153A (en) 1974-10-01
JPS58117456A (ja) 1983-07-13
BE777309A (nl) 1972-04-17
CA964560A (en) 1975-03-18
IT965020B (it) 1974-01-31
SE398557B (sv) 1977-12-27
NL154599B (nl) 1977-09-15
DE2164768B2 (de) 1976-01-22
AU467394B2 (en) 1975-11-27
AU3698671A (en) 1973-06-21
CH557030A (de) 1974-12-13
NL7018838A (da) 1972-06-30
IL38371A0 (en) 1972-02-29
JPS5834783B1 (da) 1983-07-28
JPS58117455A (ja) 1983-07-13
EG11604A (en) 1977-08-15
FR2120835A5 (da) 1972-08-18
BR7108553D0 (pt) 1973-07-03

Similar Documents

Publication Publication Date Title
DK150690B (da) Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stofved enzym-immunoanalyse
USRE31006E (en) Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3850752A (en) Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US4828985A (en) Antibodies against the complex of a small molecule and its binding protein, their preparation and their use in diagnostic methods
US3791932A (en) Process for the demonstration and determination of reaction components having specific binding affinity for each other
US4235960A (en) Competitive enzyme-linked immunoassay
USRE29169E (en) Process for the demonstration and determination of reaction components having specific binding affinity for each other
US4232001A (en) Methods and materials for detection of estrophilin
US4427781A (en) Particle agglutination immunoassay with agglutinator for determining haptens; PACIA
US4477576A (en) Antigen assay method and kit
HOSODA et al. Effect of bridge heterologous combination on sensitivity in enzyme immunoassay for cortisol
US4621048A (en) Reagents containing an anti-ligand bound to an anti-enzyme and methods for employing said reagents in an immunoassy
EP0383313A2 (en) Reagent for immunoassay, and kit containing the same
EP0124366A2 (en) Method of measuring biological ligands
Mariotti et al. A new solid phase immunoradiometric assay for antithyroid microsomal antibody
US4693969A (en) Reagent for use in a sandwich solid-phase enzyme-immunoassay and process for employing same
US6555388B1 (en) Binding protein capture assay
JPH0731191B2 (ja) チログロブリンを使用する甲状腺ホルモンの免疫定量法
US9891214B2 (en) Immunological assay method
EP0554458B1 (en) Immunoassay and monoclonal antibody for determining diarrheal shellfish poisons
JPH081436B2 (ja) 生物学的液体中の遊離リガンドの測定方法および測定用キット
EP0338045B1 (en) Solid-phase non-separation enzyme assay
Dericks-Tan et al. Pseudohypergonadotropinemia and pseudohyperprolactinemia induced by heterophilic antibodies?
Read et al. Experiences with the haemagglutination method of human growth hormone assay
EP0390870A1 (en) Method for detection of premenstrual syndrome